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Human cells are routinely exposed to DNA-damaging conditions, from both external 
sources like ionizing radiation and internal sources like normal oxidative metabolism. 
Damage in the form of double strand breaks (DSBs) is especially problematic. DSBs 
occurring outside of replication forks can be repaired through two forms of homologous 
recombination. The first of these is genetic conversion involving either RPA, BRCA1, 
PALB2, BRCA2, and RAD51, or RPA, RAD52, RAD51, and other unknown factors. The 
second is single strand annealing involving RPA and RAD52. Familial breast cancers, 
among numerous others, are characterized by homozygous pathological mutations in 
the BRCA2 pathway and must therefore rely on the RAD52 pathway for remediation of 
DSBs. Inhibiting the interaction between RPA and RAD52 should therefore selectively 
terminate such cancer cells without harming healthy cells. Structural information 
regarding RAD52 and the phosphorylation state of RPA during active DNA repair must 
be elucidated to achieve this. Initial structural data for RAD52 was acquired using small 
angle X-ray scattering (SAXS). Using the available RAD52(1- 212) crystal structure we 
were able to estimate the orientation of the RAD52(1-303) SAXS structure. The 
application ITASSER allowed for the modeling of one of the RAD52(213-303) sections 
which is outside of the RAD52(1-212) crystal structure, and which includes the RPA 
binding domain. Utilizing available information about known DSB-induced 
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phosphorylation sites of RPA, paired with data from Phosida and PhosphositePlus, 
eleven candidate sites were selected for structural and DNA binding studies. 
Phosphorylation was mimicked by mutation of candidate sites to glutamic acid, and 6 of 
the combinations tested retained heterotrimer stability. Phosphomimetic mutations to the 
RPA70 subunit decreased DNA binding affinity. Identification of these stable 
phosphomimetics with confirmed DNA binding activity provides tools for experiments 
delving into the activities of RPA functioning in BIRDSB repair, these tools will also be 
used for structural experiments involving the binding of RPA to DSB repair proteins, 
including the SAXS compatible RAD52(1-303). 
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Chapter I: Introduction 
1.1 DNA Damage and Repair  
It is impossible for an organism to live and thrive without developing ways to protect 
and repair its genome from deoxyribose nucleic acid (DNA) damage. Factors that induce 
DNA damage come from a variety of sources with a multitude of them being unavoidable. 
Exogenous sources include environmental toxins such as byproducts of tobacco usage, 
environmental radiation sources such as radon gas, and ionizing radiation such as 
ultraviolet light and X-rays. If an organism were able to somehow avoid all exogenous 
factors, endogenous factors can still threaten cells with DNA damage. Many of the factors 
are intrinsically linked to how cells function. These include replication errors, free radical 
generation through metabolism, and alkylating agents [1]. All of these factors combined 
result in a genome that is constantly under attack, and without a way to detect and repair 
this damage the cells will die or turn cancerous. 
This damage is mitigated through the activation of the DNA damage response 
(DDR) and can result in the activation of multiple DNA repair pathways. The pathway 
chosen depends on the type of damage and phase of the cell cycle. Damage to a single 
strand of DNA can be repaired through either the mismatch repair pathway (MMR), the 
base excision repair pathway (BER), or the nucleotide excision repair pathway (NER).  
The MMR pathway is used if an incorrect nucleotide is used during DNA replication 
or a nucleobase becomes damaged, for instance through deamination (Figure 1.1) [2]. 
The mismatched bases are recognized and bound by the sliding clamp proteins MutSα or 
MutSβ. These will recruit the sliding clamp protein MutLα. This pair of sliding clamps will 
shift either in the 5’ or 3’ direction from the mismatch site. If the clamps move 5’ of the site, 
they will encounter the protein replication factor C (RFC). RFC loads the homotrimeric 
proliferating cell nuclear antigen (PCNA) onto the 3’ end of a nick or Okazaki  
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Figure 1.1 MMR pathway overview 
The MMR pathway begins when MutSα or MutSβ binds to the mismatch site (red line) 
and recruits MutLα. These proteins undergo a conformational shift allowing the 
proteins to act as sliding clamps and move away from the mismatch site. A) Clamps 
migrating in the 5’ direction will encounter RFC bound to the 5’ terminus of the break. 
RFC is displaced and EXO1 is loaded onto the DNA. This endonuclease will then 
degrade the DNA in a 3’ direction with the resulting gap stabilized by RPA. The removal 
of the mismatch halts the stimulation of EXO1 by MutSα and begins the inhibition of 
EXO1 by MutLα. POLD binds PCNA at the 5’ end of the gap and fills the gap. The 
remaining nick is repaired by LIG1. B) Clamps migrating in the 3’ direction come upon 
PCNA bound to the 3’ terminus of the break. EXO1 is recruited and loaded onto the 
DNA, possibly multiple times, until the region between the mismatch and the break in 
degraded. RFC bound at the break will prevent EXO1 from degrading further away 
from the mismatch in a 3’ direction. Degradation of the mismatch results in the 
inhibition of EXO1 by RPA and MutLα. PCNA will recruit POLD and this complex will 
fill in the gap. The remaining nick is repaired by LIG1. 
 
3 
 
 
 
  
 
 
4 
 
fragment, becomes displaced, and exonuclease 1 (EXO1) is loaded onto the DNA. EXO1 
is stimulated by MutSα and degrades the DNA in a 3’ direction until it degrades the 
mismatch. This removal of the mismatch ends the stimulation by MutSα and initiates 
inhibition of EXO1 by MutLα. DNA polymerase δ (POLD) binds to PCNA and fills in the 
gap. The remaining nick is repaired by DNA ligase 1 (LIG1). Should the sliding clamps 
shift 3’ of the mismatch site encounter PCNA that was recruited by RCF to the 3’ terminus 
of a nick, and EXO1 will be loaded onto the DNA. RCF prevents EXO1 from degrading 
further from the mismatch in a 3’ direction. EXO1 may need to be loaded onto the DNA 
multiple times to complete the degradation of the DNA to the mismatch site. Inhibition of 
EXO1 happens as described previously, and PCNA recruits POLD. POLD fills in the gap, 
and the remaining nick is repaired by a LIG1. 
The BER pathway is used to repair a damaged base or apurinic/apyrimidinic (AP) 
site (Figure 1.2) [3]. The pathway begins with a glycosylase recognizing and binding to 
the damaged base and excising it to create an AP site. An AP nuclease will then make a 
nick 5’ of the AP site. A polymerase, such as polymerase β (POLB), binds and fills in the 
gap caused by the nick and missing base. In long patch BER the polymerase will displace 
bases beyond the AP site, and flap endonuclease 1 (FEN1) then removes the displaced 
ssDNA flap. The remaining nick is repaired by LIG1. In short patch NER, POLB binds, fills 
in the single nucleotide gap, and removes the 5’-terminal deoxyribophosphate (dRP). The 
remaining nick is repaired by DNA ligase 3 (LIG3). 
The NER pathway is used when a damaged DNA lesion is distorting the DNA helix, 
such as a DNA adduct or thymidine dimer (Figure 1.3) [4]. The early steps of this pathway 
can occur in two ways, with the first being global genome nucleotide excision repair (GG-
NER). In this form of the pathway the protein complex xeroderma pigmentosum group C-
complementing protein (XPC), RAD23 homologue B (RAD23B), 
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Figure 1.2 BER pathway overview 
A damaged base is recognized and acted upon by a glycosylase to create an AP site. 
The AP endonuclease then makes an incision 5’ of the AP site. In long patch BER (left) 
a DNA polymerase such as POLB fills in the gap and displaces a section of ssDNA 
longer than a single base. FEN1 cleaves the ssDNA flap, and LIG1 repairs the nick. In 
short patch BER (right) a polymerase such as POLB will fill in the missing nucleotide 
and cleave the remaining 5’ terminal dRP. The nick is repaired by LIG3. 
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Figure 1.3 NER pathway overview 
1-3) In GG-NER (left) the XPC, RAD52B, and CETN2 complex and UV-DDB complex 
detect lesions which distort the DNA. When that form of damage is detected RAD23B 
leaves the complex. In TC-NER (right) the DNA damage is detected by the stalling 
during elongation of RNA Pol II bound with UVSSA, USP7, and CSB. Once RNA Pol 
II stalls at the lesion, CSB forms a complex with CSA, possibly inducing reverse 
translocation of RNA Pol II. 4) TFIIH binds to the DNA lesion along with XPG. TFIIH 
uses its helicase activity to further unwind the DNA around the lesion. The TFIIH 
subunits XPD and XPB verify the presence of the lesion. RPA then binds the 
undamaged strand of DNA and XPA is recruited. 5) CAK dissociates from TFIIH. XPF-
ERCC1 is recruited by XPA and positioned by RPA, where it then makes a cut 5’ from 
the lesion. XPF-ERCC1 loads PCNA onto the DNA strand. 6) XPG cuts 3’ of the lesion 
site resulting in the release of the damaged DNA segment. 7) PCNA recruits an 
appropriate DNA polymerase for the gap filling reaction. 8) The new section of DNA is 
ligated by either LIG1 or LIG3.  
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and centrin 2 (CETN2) as well as the ultraviolet radiation-DNA damage-binding protein 
(UV-DDB) complex detect lesions which distort the DNA helix. When a damaged site is 
found, the complexes will bind and RAD23B will dissociate. In the second form of the 
pathway, known as transcription-coupled NER (TC-NER), damage is recognized by the 
stalling of RNA polymerase II (RNA Pol II) at a lesion during transcription elongation. The 
proteins UV-stimulated scaffold protein A (UVSSA), ubiquitin-specific-processing protease 
7 (USP7), and Cockayne syndrome protein (CSB) all transiently interact with RNA Pol II. 
Once RNA Pol II stalls at the DNA damage CSB forms a complex with the WD repeat 
protein (CSA), possibly inducing reverse translocation of RNA Pol II. Both of the forms of 
the pathway converge at this point, with transcription initiation factor II H (TFIIH) binding 
to the DNA damage. The xeroderma pigmentosum group G-complementing protein (XPG) 
will bind to the repair complex, and the CDK-activating kinase (CAK) will dissociate from 
TFIIH. TFIIH will use its helicase activity to further unwind the DNA around the lesion. The 
TFIIH subunits XPD and XPB verify the presence of the lesion. RPA will then bind the 
undamaged strand of DNA and xeroderma pigmentosum group A-complementing protein 
(XPA) is recruited. The protein complex of xeroderma pigmentosum group F-
complementing protein (XPF) and excision repair cross-complementing (ERCC1) (XPF-
ERCC1) is recruited by XPA and positioned by RPA, where it then makes a cut 5’ from 
the lesion. XPG then cuts 3’ of the lesion site resulting in the release of excision of the 
damaged DNA segment. PCNA is loaded onto the DNA stand by XPF-ERCC1 and recruits 
an appropriate DNA polymerase for the gap filling reaction. The new section of DNA is 
ligated by either LIG1 or LIG3. 
If the damage to a single strand of DNA is exacerbated or if stronger DNA 
damaging conditions occur then the most dangerous form of DNA damage, known as a 
double strand break (DSB), can ensue [5, 6]. This form of DNA damage impairs both DNA 
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strands simultaneously, preventing the use of the other strand as a template for repair. 
Despite being so dangerous, this form of DNA damage is not uncommon, as during S 
phase a human cell will undergo approximately 50 DSBs [7]. Repairs for DSBs occur using 
three pathways, the choice of which being dependent on the phase of the cell cycle among 
other factors [8].  
The most prevalent pathway used for DSB repair is non-homologous end joining 
(NHEJ) (Figure 1.4) [9, 10]. In this pathway the ends of the DSB are processed by different 
complexes of polymerases, nucleases, and ligases. Regions of existing microhomology 
can be used to guide the repair process, but nucleotides can be added or removed on 
both sides of the DNA break to create homology as well. The ends of the processed DSB 
are then ligated together [11-18]. 
If the cell is in S or G2 phase it can use the homologous recombination (HR) 
pathway to repair DSBs (Figure 1.5) [19-21]. HR uses a section of homologous sequence, 
usually on a sister chromatid or a nearby repeated sequence, to fill in the gap left by the 
DSB [22]. There are three forms to this pathway: gene conversion (GC), single strand 
annealing (SSA), and break induced repair (BIR). GC has two forms called the double 
strand break repair pathway (DSBR) and the synthesis dependent strand annealing 
pathway (SDSA) [23]. These pathways differ in their resolution, but begin the same. On 
each side of a DSB the 5' strand is resected to leave a 3' overhang using the MRN complex 
(composed of the proteins mitotic recombination 11 (MRE11), RAD50, and nijmegen 
breakage syndrome 1 (NBS1)), as well as the proteins CtBP-interacting protein (CtlP), 
bloom syndrome RecQ like helicase (BLM), exonuclease 1 (EXO1), and DNA replication 
helicase /nuclease DNA2 [24, 25]. RAD51 is loaded onto the 3' strand with the help of 
multiple mediator proteins [23], and performs strand invasion on a homologous sequence, 
possibly on a sister chromatid [22, 26]. After D-loop formation, this sequence 
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Figure 1.4 NHEJ pathway overview 
An intact DNA strand (A) that undergoes a DSB (B). The KU70-KU80 heterodimer 
binds to the DSB ends and assists the binding of NHEJ polymerase, nuclease, and 
ligase complexes (C). Regions of microhomology (circled) can be used to guide the 
repair process (D, top). Bases can be removed or added to create sequence homology 
as well (D, middle and bottom, black text indicates added bases). 
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Figure 1.5 HR GC pathway overview 
A) A DSB is formed. B) The ends of the DSB are bound by the MRN complex. ATM is 
recruited, which leads to the phosphorylation of γH2AX. C) BRCA1 interacts with the 
damage site and inhibits 53BP1. This inhibits activation of the NHEJ pathway. D) CtlP, 
EXO1, and DNA2 resect the 5’ ends of the DSB leaving a 3’ overhanging ssDNA which 
quickly becomes bound by RPA. E) RPA then assists in activating ATR, which in turn 
phosphorylates PALB2 and RPA. This phosphorylation promotes the interaction 
between BRCA1 and PALB2, leading to the binding and activation of BRCA2. BRCA2 
replaces RPA on the ssDNA and recruits RAD51 (left). There is an alternate pathway 
involving the protein RAD52 replacing RPA on the ssDNA and recruiting RAD51 (right). 
Less is known about this pathway, and key components are still awaiting discovery. F) 
RAD51 forms a nucleofilament and performs strand invasion on a homologous 
chromosome. G) If the SDSA pathway is used, then crossover products are not 
produced (left). If the DBSR pathway is used, then crossover products can be formed 
(right). 
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is used to fill in the missing sections of the damaged strands. There are two sets of 
mediators that recruit and activate the RAD51 recombinase. The primary pathway involves 
the interaction of replication protein A (RPA), breast cancer type 1 susceptibility protein 
(BRCA1), partner and localizer of BRCA2 (PALB1), and breast cancer type 2 susceptibility 
protein (BRCA2) to recruit RAD51, while the alternate pathway involves RPA, RAD52, and 
some unknown mediators to recruit RAD51.  
The second HR pathway, single strand annealing (SSA), does not require alternate 
DNA strands to function. In this pathway the DNA is again resected on both sides of the 
break by exonucleases, and the 3’ overhanging strands are annealed together at a section 
containing a repeated sequence by RAD52. The overhanging flaps are cut off, and the 
DNA strands are ligated [27, 28].  
The final pathway is BIR, which is used to repair one sided DSBs that occur at 
replication forks and to assist in the maintenance of telomere length (Figure 1.6) [29-33]. 
It follows the same pattern of resection of the 5’ stand to create a 3’ overhang that the 
other two pathways use, but due to the nature of the break at the replication fork there is 
only a single end that seeks out a homologous sequence.  
This research focuses on the interaction between RPA and RAD52, specifically as 
it applies to the regulation of RPA:RAD52 binding during DSBs.  
 
1.2 RPA Activities 
RPA is an essential player in nearly all forms of the DDR. The MMR pathway sees 
RPA binding to the nicked DNA and recruiting the MMR initiation complex, which then 
later promotes mismatch-promoted excision [34]. During BER, RPA will stimulate the 
completion of the final steps of long-patch BER and will bind with the protein uracil DNA 
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glycosylase (UNG), a potentially important element of the pathway [35, 36]. In the NER 
pathway, RPA will interact with XPF-ERCC1 and possibly XPA, both of which are 
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Figure 1.6 BIR pathway overview 
A) The 5’ end of the broken strand (blue) is resected, generating a length of 3’ ssDNA. 
B) RAD51 forms a nucleofilament and performs strand invasion onto a homologous 
chromosome (orange), forming a D-loop. C) New DNA (black) is synthesized using the 
homologous chromosome as a template. D) The BIR replication bubble follows DNA 
synthesis, resulting in an extended ssDNA tail behind the bubble. E) DNA is 
synthesized along the extended ssDNA. 
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required for the repair process [37-40]. RPA will also bind and stabilize the exposed length 
of single stranded DNA (ssDNA) that occurs during this pathway, stimulate the rate of the 
NHEJ pathway, and co-localize at KU80 foci [37, 41, 42]. In HR pathways, RPA is 
responsible for binding and stabilizing the 3’ overhang that occurs in each pathway, 
recruits a host of downstream mediator and DNA repair proteins, and interacts with 
multiple checkpoint proteins [43-49]. During HR RPA co-localizes with various HR factors 
at DNA damage sites, and will directly associate with RAD51 [50-52]. Of particular interest 
is the interaction between RPA, BRCA2, and RAD52.  
 
1.3 RPA Structure 
The unique architecture of RPA involves the presence of six oligosaccharide 
binding folds (OB-folds) divided amongst the heterotrimeric protein subunits (Figure 1.7). 
These subunits are named for their respective molecular weight (MW) and are therefore 
labeled RPA70, RPA32, and RPA14 ordered largest to smallest, respectively. RPA70 
contains four OB-folds making up the DNA binding domains (DBDs) labeled A, B, C, and 
F domains of the protein. DBD-A and B have the highest ssDNA affinity and are thought 
to initiate the ssDNA binding process. DBD-F has low ssDNA affinity and is responsible 
for the interaction with multiple other proteins. DBD-C binds ssDNA with higher affinity 
than DBD-F but with lower affinity than DBD-A and B as well as interacts with the other 
RPA subunits to form the trimer core. There is evidence that a region of DBD-A (amino 
acids 169-326) can bind with the protein RAD52 [47]. RPA32 is comprised of the DBD-D, 
the winged helix-loop-helix (wHLH) domain responsible for further interaction with other 
proteins, and an N-terminal unstructured region known to become hyper-phosphorylated 
in circumstances of DNA damage [53, 54]. The final subunit, RPA14, is composed of a 
single  
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Figure 1.7 RPA domain map 
The original domain map published by Dr. Marc Wold (1997). RPA is a heterotrimeric 
protein composed of the RPA70, RPA32, and RPA14 subunits, named for their 
respective MWs. Thicker regions represent structured domains, while thin white bands 
represent unstructured linker regions. The six OB fold domains are DBD-A (orange), 
DBD-B (yellow), DBD-C (green), DBD-D (blue), DBD-E (purple), and DBD-F (pink). 
DBDs C, D, and E interact with each other to form the trimer core. Interactions with 
other proteins occur through DBD-F, DBD-A, and the wHLH domain.  
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OB-fold domain named DBD-E and does not participate in DNA binding. This subunit 
functions to stabilize the heterotrimer [43, 55].  
 
1.4 RPA Post -Translational Modifications  
A form of post-translational modification of RPA is phosphorylation. This 
phosphorylation occurs both during the cell cycle and in response to DNA damage. 
Phosphorylation occurs at Ser23 and Ser29 during the S/G1 phase transition and during 
M phase [53, 56-60]. RPA undergoes different patterns of phosphorylation depending on 
the type of DNA damage [61, 62]. The hyper-phosphorylation of RPA that occurs in 
response to DNA damage has been well documented but the specifics of its effect on 
activity is poorly characterized [61-63]. Hyper-phosphorylation has been linked to the 
breaking up of the heterotrimer as well as steps leading to apoptosis [64, 65]. DNA 
damage-induced hyper-phosphorylation of RPA is currently thought to be carried out by 
the PIKK family proteins DNA-PK (for NHEJ), ATM, and ATR (for HR) [66-68]. In the 
appropriate cell cycle for HR where cells have undergone DSBs, capillary isoelectric 
focusing data has shown that there can be up to 14 phosphorylations on RPA [69]. Even 
in cells without DSBs the majority of RPA has between 2 and 4 phosphorylations. The 
phosphorylation state of RPA has been shown to regulate its interaction with other 
proteins, such as RAD52 [47, 70, 71]. Evidence has shown that there is a possibility that 
hyperphosphorylation of RPA can shift its role from DNA replication to DNA repair [72-74].  
 
1.5 RAD52 Activities 
RAD52 was originally identified in yeast during a screen of mutations responsible 
for sensitivity to radiation, and is the primary mediator of recombination in yeast [75-77]. 
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This protein is essential in yeast, as knockout mutations show severe defects in all HR 
pathways, SSA, mating type switching, meiosis, integration of homologous DNA into the 
genome, and spore viability [78-80]. In mammals however, the protein is non-essential. A 
knockout of the protein in mouse embryonic stem cells showed no increase in sensitivity 
to radiation, but there was a decrease in levels of HR [81]. RAD52-/- mice showed no 
changes in their viability and fertility [81]. This drastic shift from the changes which occur 
in yeast in the same conditions was repeated in chicken DT40 cells [82]. These cells 
showed no change in the formation of RAD51 foci or levels of DSB repair. Because of 
these studies interest in RAD52 waned for a period. Research eventually surfaced, 
however, that showed that RAD52 did in fact have a vital role in HR. In cells with 
deficiencies with BRCA1, PALB2, and BRCA2, knockdown of RAD52 proved lethal [83, 
84]. RAD52 is part of an alternate HR pathway, where it takes up the mediator role of 
BRCA2. In this alternate HR pathway RAD52 will bind to RPA, assist in displacing it from 
the ssDNA, and recruit RAD51 [77, 85-87]. Outside of HR, RAD52 has been shown to 
carry out multiple functions including the repair of stalled replication forks, strand 
exchange between short lengths of ssDNA and dsDNA, and reverse strand exchange 
between RNA and DNA [88-92]. It is also possible that RAD52 promotes BIR independent 
of RAD51 [29].  
 
1.6 RAD52 Structure 
RAD52 is composed of an ordered N-terminal region and a disordered C-terminal 
region (Figure 1.8). In the N-terminal region amino acids 39-80 form the DBD and amino 
acids 85-159 form the self-binding domain [90, 93, 94]. The unstructured carboxyl (C) -
terminal domain (CTD) contains another RPA binding region mapped to the amino acids 
221-280, as well as the RAD51 binding domain at 290-330 [46, 47, 95].  
20 
 
 
  
 
Figure 1.8 RAD52 domain map 
The original domain map published by Park et. al (1996). The N-terminal half of RAD52 
contains the DNA binding domain (orange) and the RAD52 self-binding domain (green). 
The C-terminal half contains the RPA binding domain (blue) and the RAD51 binding 
domain (brown). The thick N-terminus indicates the structured region of this protein, while 
the thin C-terminus indicates the unstructured region. 
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A nuclear magnetic resonance (NMR) structure of the RPA32 wHLH domain shows the 
amino acid sequence 257-274 of the RAD52 RPA binding domain forming a α-helical 
structure and interacting with the RPA32 wHLH domain through amino acids Arg260, 
Gln261, and Lys262 [54]. Electron micrographs of the full length recombinant protein show 
it assembled into a heptametrical (7-mer) ring [96]. The unstructured CTD has prevented 
crystallization of the full length protein, and the size of the protein has prevented analysis 
by NMR, but crystal structures exist for the ordered N-terminal regions of RAD52(1-209) 
and RAD52(1-212) [97, 98]. In these crystals the protein forms an undecamer (11-mer) 
ring with the DNA binding grooves of each subunit open on the same face of the oligomer. 
Amino acids 218-418 have been shown to be responsible for the formation of even larger 
aggregates of RAD52 [99]. With the RPA binding domain outside of the structured region 
of the protein, and the only structural information on the interaction between RAD52 and 
RPA currently being a 18 amino acid peptide sequence (RAD52(257-274)) bound to a 
single RPA domain, more research into the full mechanism of RPA and RAD52 interaction 
is needed.  
 
1.7 RAD52 and RPA Interactions 
RPA and RAD52 are confirmed to interact in multiple situations during the DDR. 
DSBs incurred outside of S or G2 phase can use SSA to repair the damage. The exposed 
ends of the DSB are bound by the MRN complex and CtlP [24, 25]. The helicase BLM is 
then recruited along with the endonucleases EXO1 and DNA2 [24]. These proceed to 
resect the 5’ strand, creating long 3’ overhanging ends on both sides of the DSB. RPA 
binds these exposed 3’ strands and recruits RAD52. RAD52 then displaces RPA on the 
ssDNA and proceeds to anneal the 3’ strands together at a region with a repeated 
sequence on both sides of the break. The remaining overhanging 3’ flaps are cleaved by 
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the XPF-ERCC1 complex, and the nicks ligated to form an intact DNA strand, albeit one 
with sections adjacent to the break cut away resulting in a loss of genetic information [100]. 
If DNA damage occurs during S or G2 phase, then RPA and RAD52 can also participate 
in an alternate HR pathway. After initiation, HR begins with strand resection as described 
previously, with the MRN complex binding the broken DSB end resecting the 5’ ends 
around the DSB to provide exposed 3’ ssDNA. RPA binds to this ssDNA and begins the 
recruitment of BRCA1. BRCA1 in turn recruits PALB2, which recruits/activates BRCA2. 
BRCA2 will bind to RPA and remove it from the DNA strand while recruiting, binding, and 
stimulating RAD51 recombinase. RAD51 will assemble into a helical nucleoprotein 
filament and perform strand invasion into the homologous sequence of a sister chromatid, 
forming a Holliday junction. If the DSBR pathway is used then the 3’ ssDNA which was 
not involved in strand invasion will form a second Holliday junction with the invaded 
chromosome. A nicking endonuclease is then utilized to resolve the double Holliday 
junctions [23]. Depending on how the Holliday junctions are cut by the nuclease, a 
crossover product can be formed. If the SDSA pathway is used, only a single Holliday 
junction is formed, and the extended 3’ invading stand is released in a process called 
branch migration. It then rebinds with the other 3’ resected strand and polymerases fill in 
the missing nucleotides[23]. The SDSA pathway does not produce crossover products 
[101]. GC pathways result in no loss of genetic information as any damaged or missing 
components are copied over from the homologous sequence. There is an alternate form 
of this pathway that is less explored. In this alternate pathway following RPA binding to 
the newly resected ssDNA strands, RAD52 is recruited. It then assists in displacing RPA 
from the ssDNA, and recruits RAD51. The pathway then proceeds much as the BRCA2 
pathway. This alternate pathway is of great interest because cancers which have 
deficiencies in key members of the BRCA2 pathway are dependent on the RAD52 
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alternate pathway to accurately repair their DSBs. If the molecular mechanism behind the 
interaction of RPA and RAD52 could be discovered, then a focus on the disruption of that 
mechanism could lead to new potential targets for cancer drugs that would target cells 
with this so-called RAD52 addiction while leaving healthy cells intact. 
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Chapter II: Deduction of an Experimental Model of RAD52(1-303)  
2.1 Introduction 
The inactivation of the alternate HR pathway involving the interaction between 
RPA and RAD52 has been found to be synthetically lethal with deficiencies in the BRCA2 
mediated HR pathway [83, 84]. This means that cells which have either functional BRCA2 
HR or RAD52 HR will continue to divide and thrive. If both pathways are made deficient 
simultaneously the cells are unable to survive. This is of great interest as members of the 
BRCA2 pathway are known to be mutated in various cancers including breast, pancreatic, 
and ovarian cancers [102-106]. In cancers featuring a defective BRCA2 pathway, 
inhibition of RAD52 activity would provide a way to selectively terminate the cancer cells 
while leaving healthy cells unharmed. To this end finding a way to inhibit the interaction 
between RPA and RAD52 is a great potential drug target.  
This potential is held back by the fact that structural data on the full individual 
proteins as well as of the complex itself is not available. RPA and RAD52 both contain 
significant levels of unstructured regions that prevent the crystallization of these proteins 
as well as inhibiting the effectiveness of NMR techniques with them. It was possible to 
both crystalize and collect NMR data on specific ordered domains for both proteins [54, 
97, 98, 107-110]. This leads us to an alternate way of getting the structure of these proteins 
as they interact.  
Small angle X-ray scattering (SAXS) does not suffer the crystallization 
requirements of X-ray crystallography nor does it have the size and mobile region 
restrictions of NMR, however these bonuses come at the cost of resolution. This drawback 
can be partially overcome by docking the existing domain structures for the proteins with 
their respective SAXS envelopes. This allows us to compare the shifts in the SAXS 
envelopes of the individual proteins to identify where the structured domains are oriented, 
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giving us the binding surface. SAXS data can be interpreted in the following ways. The 
scattering data can be plotted in three ways, the Guinier plot, Kratky plot, and the pair 
distance distribution function (P(r)) (Figures 1.9 and 1.10). The Guinier plot will give 
information about the radius of gyration (Rg) as well as serving as a data quality control. 
The Guinier plot should be linear, as linear means that the sample was monodisperse. If 
the plot smiles or frowns then there was a problem with aggregation or repulsion effects 
and further processing cannot be done. The SAXS unit can be calibrated with a MW 
standard so that the intensity at zero concentration will give an estimate of MW. The 
second plot that can be used is the Kratky plot. This plot gives information on how globular 
or well-folded the protein is. A folded protein shows a peak followed by a return to the 
baseline while unfolded proteins show more of a horizontal asymptote depending on the 
degree to which they are unfolded. The third plot is the P(r) plot. This plot shows the 
probability that a random pair of atoms will have a specific distance from each other. 
Envelopes are generated from the P(r) function. The r intercept of the P(r) function is the 
farthest distance between a pair of atoms in the molecule or Dmax. The P(r)max shows the 
most common distance between pairs of atoms.  
The objective for this portion of the project is to acquire initial structural data of the 
RPA binding domain on the RAD52 unstructured C-terminal domain using SAXS. SAXS 
data was gathered on RAD52(1-212) and on RAD52(1-303) and ab initio protein 
envelopes generated. RAD52(1-303) was chosen for these experiments because it 
contains the RPA binding domain and can be purified to a polydispersity compatible with 
this technique. RAD52(1-212) was selected because docking its existing crystal structure 
with the RAD52(1-212) SAXS envelope can give us the alignment of the structure. The 
RAD52(1-212) SAXS envelope was then aligned with the RAD52(1-303) SAXS envelope, 
conferring the alignment of the crystal structure and allowing us to infer the placement of  
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Figure 1.9 Interpreting the SAXS scatter plot and Guinier plot 
A) A SAXS scatter plot. Y axis is a log of the intensity value, X axis is the inverse 
distance from the center of the scattering plot. Low resolution data is closer to the Y 
axis. The Guinier and Kratky plot are made by regraphing this data. 
B) Corresponding Guinier Plot. This plot is made from the low q range data. The slope 
of the best fit line gives the Rg of the molecule. The Y-intercept value gives the intensity 
at 0 concentration (I(0)), which when paired with MW standards can give the MW of 
your molecule. Should this line curve up (or “smile”) it would indicate that aggregation 
has occurred. If the line should curve down (or “frown”) it would indicate that 
intraparticle repulsion is occuring. Both situations require the data collected to be 
disgarded.  
  
 
27 
 
 
 
 
Figure 1.10 Interpreting the Kratky plot and Pair Distribution Function 
C) A cartoon of the Kratky plot. Globular (well-folded) proteins will form a bell shaped 
curve that returns to the baseline (blue). Extended or partially unfolded molecules will 
not have this return to the baseline, and will often have a rise in higher q values 
(orange). Completely unfolded proteins rise into a horizontal asymptotic curve and 
show little or no drop back to the baseline (green).  
D) A schematic drawing of the of the P(r) plot. The line gives the pair-wise distance 
between atoms in the molecule. The maximum r value (Dmax) gives the longest 
dimension of the molecule. The maximum Y value (Ymax) gives the most common 
distance between atoms in the molecule. The curvature of the plot contains information 
about the shape of the molecule. Pictured here are representative curves for rod 
(yellow), sphere (blue), and barbell (green) shapes.  
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the unstructured C-terminal amino acids. With this in mind a model of the C-terminal 91 
amino acids was generated and added to the crystal structure. Put together, these actions 
provided the orientation of the RAD52(1-303) molecule as well as some insight into where 
the C-terminal amino acids, including the RPA binding domain, may be located. 
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2.2 Methods 
2.2.1 Recombinant Protein Expression 
The RAD52(1-212) pET28a expression plasmid was created by Gilson Baia in Dr. 
Gloria E.O. Borgstahl’s Lab. The pET28a expression plasmids for RAD52 and RAD52(1-
303) were a gift from Dr. Min Park. Rosetta2 E. coli cells were transformed using the 
manufacturers’ protocols (Novagen). Selection of transformed cells was done on agarose 
plates containing 30 µg/ml kanamycin and 34 µg/ml chloramphenicol. Colonies that 
survived the selection process were grown in lysogeny broth (LB) media incubated at 37 
°C with 170 rpm shaking until they reached an optical density at 600 nm (OD600) between 
0.7 and 0.9. At this point the cells were induced with 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and further incubated for an additional 4 hours. Cells were 
harvested by centrifugation at 14,000 xg and stored at -20 °C.  
  
2.2.2 Protein Purification 
Cell pellets were thawed and suspended in HisTrap running buffer (50 mM Tris-
HCl, pH 7.8, 300 mM KCl, 10 mM imidazole, 10% glycerol, 2 mM 2-mercaptoethanol 
(BME)). A protease inhibitor cocktail (PIC) (SIGMA) compatible with histidine-tagged 
proteins was added at a level of 250 µl per gram of cell pellet. Lysis of the bacteria was 
achieved by three passes through an Emulsiflex-C3 at 15,000 psi. Centrifugation for 30 
minutes at 40,000 xg separated the cellular debris from the protein-containing 
supernatant. The supernatant passed through a 0.45 µm HV DuraporeR membrane filter 
(MILLIPORE). Purification of the protein was achieved using the process described in 
Kagawa W. et al., (2002), and Ranatunga W., et al., (2001), with the following changes. 
All column chromatography purification was done using an ÄKTApure (GE Lifesciences). 
The protein was first purified on a HisTraptm HP chromatography column (GE 
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Lifesciences). The column was equilibrated with 5 CV of HisTrap running buffer, then the 
protein lysate was loaded. A gradient to 1 M imidazole was used to elute the protein. 
Fractions containing the protein of interest were pooled and dialyzed against the heparin 
running buffer (50 mM Tris-HCl, pH 7.5, 200 mM KCl, 10% glycerol, 0.5mM 
ethylenediaminetetraacetic acid (EDTA)). The second step in purification utilized a 
HiTraptm Heparin HP column (GE Lifesciences). The column was equilibrated with the 
heparin running buffer and loaded with the protein as described previously. Elution was 
achieved with a gradient to 1 M KCl. The protein peak was dialyzed overnight against 
RAD52 size exclusion chromatography (SEC) running buffer (20 mM Bis-Tris, pH 6.0, 10% 
glycerol, 400 mM NaCl, 100 mM KCl, 1 mM EDTA). The final step in purification used a 
HiLoad 16/600 Superdex 200 pg column (GE Lifesciences) equilibrated with 1.3 CV of 
RAD52 SEC running buffer collecting 1 ml fractions. Protein concentrations for wtRAD52, 
RAD52(1-212), and RAD52(1-303) were acquired using absorbance at 280 nm (A280) with 
extinction coefficients (ε) of 40300 M-1cm-1, 20400 M-1cm-1, and 20400 M-1cm-1 and MWs 
of 48.09 kDa, 25.22 kDa, and 34.6 kDa, respectively.   
2.2.3 Dynamic Light Scattering 
Individual protein fractions were concentrated in the RAD52 SEC running buffer 
using a 10 kDa molecular weight cut-off (MWCO) spin concentrator (GE Lifesciences). 
Multiple concentrated fractions were checked for monodispersity using a DynaPro MS/X 
with a 12 µl quartz cuvette (Wyatt Technology Corporation). Data was collected and 
processed using Dynamics 6.7.7 software (Wyatt Technology Corporation). A minimum 
concentration of 1 mg/ml was required for accurate measurement of monodispersity. With 
this system, fractions with a polydispersity of less than 20% are considered to be 
monodisperse. The washing procedure for the cuvette involved one wash with 1% 
Liquinox followed by 5 rinses with deionized water (DI). This wash procedure was 
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repeated three times. Dynamic light scattering of DI water and buffer was checked with 
the instrument to ensure the cuvette was clean before use and that the only readings were 
from the protein being tested. All samples were centrifuged at 13,000xg for 5 minutes and 
then filtered using a 0.45 µM polyvinylidene fluoride (PVDF) membrane syringe filter 
(MicroSOLV) before loading 17 µl of analyte into the cuvette in a manner that prevented 
bubble formation. The equipment performed 10 scans of 10 seconds each to acquire the 
polydispersity value. Monodisperse fractions that were adjacent to each other in the 
elution order were combined, prepared again as they were originally, and then re-
analyzed.  
 
2.2.4 Size Exclusion Chromatography with Multi-Angle Light Scattering 
Protein samples were prepared by centrifugation at 13,000xg for 5 minutes 
followed by filtration using a 0.45 µM PVDF membrane syringe filter. Size exclusion 
chromatography with multi-angle light scattering (SEC-MALS) was performed using an 
Agilent 1260 chromatography system paired with an ultraviolet detector, miniDAWN 
TREOS, Optilab T-rEX, and a WTC SEC column with WTC SEC guard column (Wyatt 
Technology Corporation). Analysis of molecular weights was done using ASTRA 6 
software (Wyatt Technology Corporation). Samples were run at 0.5 ml/min using RAD52 
SEC running buffer.  
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2.2.5 Small Angle X-ray Scattering 
SAXS analysis was performed using a BioSAXS1000 (Rigaku) with attached auto-
sampler and a FR-E rotating anode X-ray generator (λ = 1.54 Å). Concentrations were 
obtained using A280 as described previously. Images were collected for 90 minutes with 
subframes taken every 10 minutes to check for radiation damage, of which none was 
observed. Data analysis was done using the Automated Analysis Pipeline (AAP) in the 
SAXLab software. SAXSLab is a GUI for running the ATSAS package [111] running 
scripts to control the ATSAS programs, after which the results are returned to the user. 
Buffer subtraction, Guinier plot, Rg, MW, Dmax, volume, P(r), Kratky plot, the infinite dilution 
scattering curve, and ab initio bead models are all calculated through this software. 
Docking of the models with the SAXS envelopes was done with the Situs package using 
the Colores program [112, 113]. Figures were made using PyMOL (Schrödinger, LLC).  
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2.3 Results 
2.3.1. RAD52(1-212) 
2.3.1.1 Expression and Purification 
RAD52(1-212) expression was checked through visual comparison of uninduced 
and induced cells using SDS-PAGE. RAD52(1-212) elutes at 150 mM and 300 mM 
imidazole from the HisTraptm HP column. Both peaks contained RAD52(1-212) but the 
peak at 300 mM imidazole was cleaner when checked by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). This purification was simplified by 
replacing the concentration gradient with 3 CV steps at 50 mM, 150 mM, 300 mM, and 
1000 mM imidazole. Fractions collected from the 300 mM imidazole elution were more 
monodisperse and were better candidates for SAXS. RAD52(1-212) eluted from the 
HiTraptm Heparin HP column at 450 mM KCl. After this step the protein was a single band 
when investigated with SDS-PAGE and could be used for assays that did not require 
extreme levels of purity. Polished protein eluted from the HiLoad 16/600 Superdex 200 pg 
column at approximately 62 ml after injection.   
 
2.3.1.2 Dynamic Light Scattering  
Despite its purity, RAD52(1-212) purified in these conditions often would only have 
a few fractions that were monodisperse. Fractions from SEC purification had to be 
concentrated to a minimum of 1 mg/ml to reduce polydispersity, and all fractions were 
checked. DLS of monodisperse fractions revealed a polydispersity of 12.2% (Figure 2.1). 
Adjacent monodisperse fractions could be combined without any gain in polydispersity.  
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Figure 2.1 DLS of RAD52(1-212) 
An example of DLS from fractions of RAD52(1-212) which were used for SAXS. The 
polydispersity of this polydispersity was 12.2%.  
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2.3.1.3 Size Exclusion Chromatography with Multi-Angle Light Scattering 
SEC-MALS analysis also showed the protein to be monodisperse with a MW of 
229 kDa across the peak (Figure 2.2). This suggests a protein consisting of a 9.8 subunit 
ring. Using this information a model 10-mer of the RAD52(1-212) ring was created (by G. 
Borgstahl) using the program CNS-SOLVE [114, 115] (Figure 2.3). To this end six pairs 
of amino acid contacts were defined and the subunits were placed in a simulated excited 
state and allowed to reform, combining into a modified but familiar ring shape.  
 
2.3.1.4 Small Angle X-ray Scattering  
The 7.48 mg/ml concentration by itself provided the best scattering data and SAXS 
envelope, and so was not processed with accompanying concentrations (Figure 2.4).The 
Guinier plot for this concentration was linear indicating a monodisperse sample with no 
aggregation or concentration dependent effects (Figure 2.5). The Kratky plot shows a well 
folded protein (Figure 2.6). The P(r) plot showed a Dmax of 117.7 Å and the most common 
dimension to be 54 Å (Figure 2.7). Instead of the expected and familiar ring form we 
observed a partially hollow half sphere with a diameter of 120 Å using ab initio bead 
modeling (Figure 2.8). The 10-mer model created with CNS SOLVE was docked with the 
SAXS envelope and the best orientation was found to have the DNA binding region of the 
ring residing inside the curved portion of the half-sphere (Figure 2.9).  
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Figure 2.2 SEC-MALS of RAD52(1-212) 
Light scattering is shown in red, differential refractive index in blue, A280 in teal, and MW in 
black. The level MW across the peak indicates monodispersity. The MW for this molecule 
was 229 kDa, which corresponds to 9.8 subunits.  
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Figure 2.3 Creation of the RAD52(1-212) 10-mer model 
The 10-mer model of RAD52(1-212) was created by removing a 1mer from the 11mer 
crystal structure. CNS SOLVE was used to perform molecular dynamics with six 
interface contacts acting as restraints. This resulted in 10mer rings. 
38 
 
 
 
  
 
Figure 2.4 SAXS scatter plot for RAD52(1-212) 
The scattering pattern for the RAD52(1-212) protein. The concentration for this data is 
7.48 mg/ml. 
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Figure 2.5 Guinier plot of RAD52(1-212) 
The Guinier Plot of the low resolution RAD52(1-212) data is linear and therefore does 
not indicate the presence of aggregation or repulsion effects. 
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Figure 2.6 Kratky plot of RAD52(1-212) 
The Kratky plot for RAD52(1-212) shows a globular, well-folded protein with the peak 
rising and falling back close to the baseline at the higher q values. 
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Figure 2.7 P(r) plot of RAD52(1-212) 
The P(r) of RAD52(1-212) shows the Dmax to be 117.7 Å.  
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Figure 2.8 Comparison of the electrostatic surface map of the crystal structure 
and the SAXS ab initio model of RAD52(1-212) 
RAD52(1-212) viewed from the A) side and B) top. The electrostatic surface (left) and 
the SAXS ab initio bead model of RAD52(1-212) (right, green) are shown. A blue 
wireframe model has been superimposed over the bead model to highlight the central 
cavity.  
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Figure 2.9 Docking the RAD52(1-212) 10-mer with the RAD52(1-212) SAXS envelope 
The 10-mer RAD52(1-212) model docked with the RAD52(1-212) SAXS envelope. The 
best orientation was found to have the DNA binding domains of the ring situated inside the 
curved face of the SAXS envelope. A) side view. B) top view.  
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2.3.2 Rad52(1-303) 
2.3.2.1 Expression and Purification 
Purification of RAD52(1-303) was identical to that of RAD52(1-212) except for the 
following changes. HisTraptm HP purification could be done either with a gradient that 
would result in RAD52(1-303) elution at 270 mM, or through steps at 150 mM, 300 mM, 
and 1000 mM imidazole. When purified with steps the 300 mM imidazole elution contained 
the highest concentration of protein that would be monodisperse in later purification steps. 
RAD52(1-303) further purified on a HiTraptm Heparin HP column eluted at 430 mM KCl. 
At this point the protein was clean when checked by SDS-PAGE. Dialysis against the 
RAD52 SEC running buffer for at least 12 hours followed by SEC was required for protein 
monodispersity. During SEC RAD52(1-303) would elute from the Superdex 200 column 
at approximately 53 ml.  
 
2.3.2.2 Dynamic Light Scattering 
RAD52(1-303) purified in these conditions had only a few fractions that were 
monodisperse, requiring all factions from SEC to be tested separately. Adjacent 
monodisperse fractions would be combined for later experiments. DLS of these fractions 
typically resulted in a polydispersity of around 14% (Figure 2.10). 
 
2.3.2.3 Size Exclusion Chromatography with Multi-Angle Light Scattering 
SEC-MALS analysis also showed the protein to be close to, but not monodisperse 
with an average MW of 328.7 kDa across the peak, indicating a ring composed of 9.4 
subunits (Figure 2.11). The DLS information and SEC-MALS graph indicate that there are  
  
45 
 
  
 
Figure 2.10 DLS of RAD52(1-303) 
The DLS of a SEC fraction of RAD52(1-303). The polydispersity of this faction was 14%. 
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Figure 2.11 SEC-MALS of RAD52(1-303) 
Light scattering is shown in red, differential refractive index in blue, A280 in teal, and MW in 
black. The tilt in MW across the peak indicates that although the peak is nearly Gaussian, 
the protein is not truly monodisperse and has slightly higher MW on the right side of the 
peak. The calculated MW across the peak is 328.7 kDa, indicating 9.4 subunits.  
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two monodisperse peaks that blend together, yet look like a single peak. A MW of 328.7 
kDa indicates a protein consisting of a mix of nine and ten subunit rings with a higher 
concentration of nine membered rings. Using the same process as described before, a 9 
subunit model of the RAD52(1-212) ring was assembled.  
 
2.3.2.4 Small Angle X-ray Scattering 
Scattering for 1.56 mg/ml and 2.66 mg/ml were collected (Figure 2.12). The 
Guinier plots were linear for all concentrations, indicating that there were no aggregation 
or concentration dependent effects of the protein under these conditions (Figure 2.13, 
2.14, 2.15). Kratky plot analysis indicated that the protein was well-folded (Figure 2.16). 
The P(r) showed a Dmax of 174 Å and a Ymax of 59.6 Å (Figure 2.17). The SAXS envelope 
for this protein was pear-shaped with the wider region having a diameter of approximately 
120 Å and an end-to-end length of 174 Å (Figure 2.18).  
 
2.3.2.5 Docking RAD52(1-303)/RAD52(1-212) 
Using the curved dome present in both SAXS envelopes for alignment, the 
RAD52(1-212) and RAD52(1-303) SAXS envelopes were docked (Figure 2.19). This 
positioning based on the common structural feature of the two models shows a clear, 
common orientation of the two. From this we can interpret that the rounded portion of the 
wider end of the envelope will likely have the DNA binding surface of the RAD52 ring 
oriented facing this curve. 
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Figure 2.12 SAXS scatter plot of RAD52(1-303) 
Scattering curve for 1.56 mg/ml shown in black. Scattering curve for 2.66 mg/ml shown 
in blue. Extrapolated (0 mg/ml) scattering curve shown in red. 
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Figure 2.13 Guinier plot of RAD52(1-303) 1.56 mg/ml  
The Guinier Plot of the low resolution data is linear and does not show the presence of 
aggregation or repulsion dependent effects. 
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Figure 2.14 Guinier plot of RAD52(1-303) 2.66 mg/ml 
The Guinier Plot of the low resolution data is linear and does not show the presence 
of aggregation or repulsion dependent effects. 
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Figure 2.15 Guinier plot of RAD52(1-303) extrapolated data (0 mg/ml) 
The Guinier Plot of the low resolution data is linear and does not show the presence 
of aggregation or repulsion dependent effects. 
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Figure 2.16 Kratky plot of RAD52(1-303) 
Data for 1.56 mg/ml shown in black. Data for 2.66 mg/ml shown in blue. Extrapolated 
(0 mg/ml) Data shown in red. The Kratky plot for RAD52(1-303) shows a globular, well 
folded protein with the peak rising and falling back close to the baseline. 
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Figure 2.17 PDF plot of RAD52(1-303) 
Data for 1.56 mg/ml shown in black. Data for 2.66 mg/ml shown in blue. Extrapolated 
(0 mg/ml) Data shown in red. The PDF plot of RAD52(1-303) shows the Dmax to be 174 
Å, and the shape is likely a combination of a sphere and rod.  
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Figure 2.18 RAD52(1-303) SAXS envelope 
A view of the molecule from the larger diameter region down (left), from the side (center), 
and from the narrower diameter region looking up (right). The molecule is 174 Å from top 
to bottom (side view), with the larger spherical head close to 120 Å in diameter (top view). 
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Figure 2.19 Docking of the SAXS envelopes for RAD52(1-212) and RAD52(1-303) 
The curved face of the RAD52(1-212) SAXS envelope (red) fits very well into the larger 
domed region of RAD52(1-303) (green), showing the alignment of the RAD52(1-303) 
molecule. With this it can be extrapolated that the DNA binding domain of RAD52(1-
212) orients toward the top of this dome, with the C-terminal region oriented into the 
narrow lower portion of the envelope. 
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2.4 Discussion 
Published methods for purification for RAD52(1-212) produce pure and 
monodisperse RAD52(1-212). To transition this method to SAXS analysis, the end buffer 
needed to be made more accommodating to the restrictions imposed by this technique, 
so a modified buffer was employed. The lower pH of the RAD52 SEC buffer (compared to 
the other RAD52 buffers described earlier) moved the charge of RAD52 further from its 
isoelectric point, while the increased salt levels assisted with both the stability of RAD52 
and protected against prolonged X-ray exposure-induced aggregation effects in SAXS. 
DLS and SEC-MALS both showed a monodisperse protein, but SEC-MALS also showed 
a shift from the crystal structure of RAD52(1-212) to a 10-mer configuration. To reflect 
this, a 10-mer model was constructed. The Kratky plot showed the protein to be well-
folded with little to no unfolded regions. The Guinier plot showed no concentration 
dependent effects as well as little to no radiation damage of the protein over the time spent 
in the path of the X-ray beam. The PDF function indicated that the Dmax of this molecule 
was 117.7 Å with the most common inter-atom distance being 54 Å. The ab initio bead 
model gave a SAXS envelope that looks like a half sphere with a hollowed region in the 
center as opposed to the expected ring shape. This half sphere model was confirmed 
through multiple attempts and varying concentrations. The 11-mer and 10-mer models 
were docked with the SAXS envelope for RAD52(1-212). The 11-mer model would not fit 
inside of the SAXS envelope without a significant portion of the model extending outside. 
It was found that the DNA binding surface of the RAD52(1-212) 10-mer would fit well 
towards the curved region of the RAD52(1-212) SAXS envelope.  
 Purification of the RAD52(1-303) protein was comparable to the purification of 
RAD52(1-212), aside from a few details. RAD52(1-303) eluted from the HisTraptm HP by 
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a gradient does not appear as a single concentrated peak. The majority of the protein was 
a single peak, but a significant amount would continue to elute as the imidazole 
concentration increased, eventually tapering off. This was most easily observed on SDS-
PAGE gels. Our current explanation for this is that RAD52 is known to form rings and 
those rings have been shown to associate with each other. It is possible that we are seeing 
multiple forms of the RAD52(1-303) oligomer. Taking RAD52(1-303) from a HisTraptm HP 
to HiTraptm Heparin HP purification required dialysis of the protein into the heparin running 
buffer. Simple dilution of the protein resulted in an absence of protein binding to the 
column. RAD52(1-303) elution from the heparin column was very pure when examined by 
SDS-PAGE, but it was not monodisperse. To achieve monodispersity the protein had to 
be dialyzed overnight into RAD52 SEC running buffer, and purified on a Superdex 200 
column. The fractions from SEC needed to be concentrated to greater than 1 mg/ml before 
investigation by DLS. Not all fractions from SEC were monodisperse, likely because SEC 
separated RAD52 rings with different numbers of subunits. Adjacent monodisperse 
fractions could be combined and used for further experiments. SEC-MALS of RAD52(1-
303) gave a MW of 328.7 kDa indicating 9.4 subunits. This most likely means that under 
these conditions we had a mixture of a 9-mers and 10-mers, the majority being 9-mers. 
The Guinier plot of RAD52(1-303) showed no curvature, indicating that for all 
concentrations tested the protein was free from effects due to aggregation, concentration, 
and X-ray damage. The Kratky plot revealed the protein to be well folded, which was a 
little surprising given the unstructured nature of the C-terminal region. The P(r) function 
shows a maximum dimension of 174 Å and a most common atom to atom distance of 59.6 
Å. Averaging by the ATSAS program suite shows the SAXS envelop to be an oblong ovoid 
174 Å from end to end at its longest axis, and with a shape almost like a large sphere with 
an attached narrower cylinder. The top curved region of the larger spherical hemisphere 
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of this envelope has almost identical dimensions to the curved face of the RAD52(1-212) 
SAXS envelope. The 9-mer model was docked with the RAD52(1-303) SAXS envelope in 
the same orientation as the RAD52(1-212) envelope, with the DNA binding region toward 
the larger curved end. There are still 91 amino acids in RAD52(1-303) that are 
unaccounted for by the RAD52(1-212) crystal structure. The missing amino acid sequence 
was put into I-TASSER (by G. Borgstahl) to predict the most likely folding of this 
unstructured region [116-118]. This program’s methodology combines composite 
homology, where the target sequence is aligned with sequences of known structure, and 
ab initio loop modeling to generate likely structures for unfamiliar sequences. The most 
likely conformation had a Z score of 1.14, where scores above 1 indicate a good alignment, 
and a C score of -2.77, where scores greater than -1.5 indicate a correctly predicted global 
topology. It was modeled attached to a single subunit of the 9-mer model. The folded 91 
amino acids fit within the SAXS envelope (Figure 2.20). Additional experiments will be 
needed to determine the formal structure of this unstructured CTD. Performing SAXS on 
RAD52(1-303) in the presence of a strong magnetic field could help organize the multiple 
unstructured coils increasing the confidence of the SAXS envelope, as well as using a 
molecule to bind to the C-terminal amino acids and comparing the changes to the unbound 
SAXS envelope.   
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Figure 2.20 RAD52(1-303) with attached CTD 
A) The 9-mer model of RAD52(1-212) docked with the RAD52(1-303) SAXS envelope. 
The DNA binding domain of the 9-mer is oriented toward the top of the envelope. 
B) Amino acids (213-303) shown attached but fully extended to a single subunit, 
demonstrating the level of folding that must occur for this sequence to fit inside the 
envelope. 
C) The most likely model of amino acids (213-303) as predicted by ITASSER attached to 
a single subunit. The model of these C-terminal amino acids fits well inside the SAXS 
envelope.  
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Chapter III: Creating DNA Damage Response Relevant RPA 
Phosphomimetics Compatible with Small Angle X-ray Scattering 
 
3.1 Introduction 
RPA is an important and well-studied ssDNA binding protein in humans. The RPA 
heterotrimer (composed of subunits of 70-, 32-, and 14-kDa labeled RPA70, RPA32, and 
RPA14, respectively) is regulated through extensive phosphorylation. RPA is involved in 
the initiation of almost every form of DNA repair [43, 61, 119-122]. RPA becomes 
hyperphosphorylated in response to DDR activation, and the N-terminus of RPA32 
contains the majority of the phosphorylation sites in unstructured regions of the protein 
[53, 63, 72, 123, 124]. After activation of the DDR pathway three kinases belonging to the 
phosphatidylinositol 3-kinase-related kinase (PIKK) family, known as ataxia-
telangiectasia-mutated (ATM), ataxia-telangiectasia and Rad3-related (ATR), and DNA-
dependent protein kinase (DNA-PK), become active and are known to phosphorylate RPA 
[66-68]. Historically the RPA32 subunit was known to be phosphorylated due to its shift 
on SDS-PAGE so an 8D construct (amino acids Ser8, Ser11, Ser12, Ser13, Thr21, Ser23, 
Ser29, and Ser33 on RPA32, mutated to Asp residues) was made in the laboratory of Dr. 
Marc Wold to mimic this hyperphosphorylated form of RPA32 [125]. Since then much more 
RPA phosphorylation data has been produced. Databases have hundreds of 
phosphorylation sites involving all three subunits. It is time to create phosphomimetics 
based on the new data. Even with the extensive research and reviews available, as well 
as the fact that RPA plays such a key regulatory role in the DDR, information on which 
phosphorylation sites are important to the DDR let alone their individual contributions to 
the regulation of RPA are not known. Using information gathered in previous experiments 
61 
 
by our lab we attempted to make phosphomimetic variants of RPA that has undergone full 
hyperphosphorylation due to DDR activation and versions with fewer sites.  
Previously capillary isoelectric focusing immunoassay data showed that RPA in 
UM-SCC-38 cells synchronized in G2 phase contained up to 7 phosphorylations with 1, 2 
and 4 phosphorylations being most frequent (Figure 3.1, blue line). Once DSBs were 
introduced RPA had up to 14 phosphorylations present, again with 1, 2 and 4 
phosphorylations being the most populated (Figure 3.1, pink line). RPA phosphorylation- 
specific antibodies showed that Ser4/8, Ser12, Thr21, Ser23, and Ser33 on RPA32 all 
become phosphorylated in cells with DSBs, while Ser23 or Ser23 and Ser33 are 
phosphorylated in control cells due to cell cycle regulation (Figure 3.2). Using the website 
PhosphoSitePlus we acquired a list of all RPA phosphorylations that have been observed 
at least once, and selected from that list ones that are likely phosphorylated by the PIKK 
family of kinases (ATM and ATR), as those kinases are known to phosphorylate RPA after 
DSBs have been formed. This was done by checking if the phosphorylation site matched 
the ATM and ATR phosphorylation consensus sequence of S/TQ (Ser or Thr residue 
followed by a Gln). Including sites observed through western blotting in response to DNA 
damage, this left us with: Ser38, Thr180, Ser207, and T483 on RPA70, and Ser4/8, 
Ser11/12/13, Thr21, Ser23, Ser33, Ser52, Ser72, and Ser174 on RPA32. We further 
pared down the list of candidate sites by removing Ser38 and Ter483 from the RPA70 
group. Residue Ser38 in an uncharacterized CDK site in the RPA70-F domain and is 
unlikely to contribute to complex formation with RAD52 or alter ssDNA interaction. Amino 
acid Thr483 is in the zinc-finger region and its mutation would destabilize the heterotrimer. 
This resulted in our final list of phosphorylation sites to investigate: Thr180 and Ser207 on 
RPA70 and Ser4/8, Ser11/12/13, Thr21, Ser23, Ser33, Ser52, Ser72, and Ser174 on  
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Figure 3.1 Capillary isoelectric focusing of RPA from whole cell lysates 
Whole cell lysates from cells without DSBs (blue) and with DSBs (pink) were run 
through capillary isoelectric focusing before being cross-linked to the capillary wall and 
probed with α-RPA70. The shifts in pI indicate changes in phosphorylation state. 
Number of phosphorylations corresponding to the shift in pI are listed above each 
peak. (Modified from G. Borgstahl et. al, 2014) 
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Figure 3.2 Western blot of DSB induced phosphorylation 
UM-SCC-38 cells without DSBs (Control) and with induced DSBs (With Breaks). Cells 
were synchronized in either A) S phase or B) G2 phase. In S phase the cells showed 
phosphorylation of the CDK site S23, even in the absence of DNA damage. In G2 
phase the CDK sites of S23 as well as S33 also were phosphorylated in the absence 
of DNA damage. (Modified from G. Borgstahl et. al, 2014) 
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RPA32 (Table 3.1, Figure 3.3). Residue Ser207 is in DBD-A on RPA70 close to the actual 
DNA binding interface, and phosphorylation of this residue could affect DNA binding 
(Figure 3.4A). Amino acid Ser52 is located in DBD-D on RPA32 in the interface between 
RPA32 and RPA14, and phosphorylation could affect heterotrimer stability (Figure 3.4B). 
Site Ser72 is also in DBD-D on RPA32, but is located on the same face of the subunit as 
both Ser174, which is just outside the structured region, and the RPA32 N-terminus, which 
contains the majority of the candidate phosphorylation sites. This face of RPA32 could 
contain a high amount of negative charges (Figure 3.4C).  
Recombinant proteins with different combinations of candidate sites mutated to 
Glu residues were expressed and purified. This generally followed two paths, with the first 
path creating phosphomimetic combinations relevant to cells with DSB-induced 
phosphorylation, and the second path creating phosphomimetics found in control cells. 
Combinations which could form heterotrimers were repurified using the full four step 
purification and had their DNA affinity tested using surface plasmon resonance (SPR). 
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Protein Residue Notes 
RPA70 Thr 180 
Ser 207 
unstructured 
 ssDNA binding site A 
 
RPA32 Ser 4,8 
Ser 11,12,13 
Thr 21 
Ser 23 
Ser 33 
Ser 52 
Ser 72 
Ser 174 
unstructured 
 
unstructured 
unstructured 
unstructured, G2 cyclin dependent kinase site 
unstructured 
D domain, RPA14/32 protein-protein interface 
D domain 
unstructured 
Table 3.1 Candidate amino acids for mutation to Glu on RPA70 and RPA32 
Residues are listed as either part of RPA70 (top) or RPA32 (bottom), as well as their 
location on the subunit. 
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Figure 3.3 RPA domain map with candidate phosphorylation sites 
While most of the candidate sites are located in unstructured linker regions, with the 
majority of them located on the RPA32 C-terminus, some are located in ordered domains.  
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Figure 3.4 Location of candidate phosphorylation sites in available crystal 
structures 
A) Ser207 is located on RPA70 DBD-A in a position to interfere with DNA binding. 
B) Ser52 is located on RPA32 DBD-D in binding interface between RPA32 and RPA14. 
C) Ser72 is located on RPA32 DBD-D, on the same face as Ser174 and the RPA32 
N-terminal unstructured region containing the majority of the phosphorylation 
candidate sites. 
Figure prepared by G. Borgstahl using Pymol.  
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3.2 Methods 
3.2.1 RPA Phosphomimetics 
Plasmids containing recombinant proteins were ordered from GenScript. Full 
length human RPA14 was cloned into the MCS1 (Ncol/Notl) restriction site and full length 
human RPA32 was cloned into the MCS2 (Ndel/Xhol) restriction site of the pACYCDuet-
1 vector. Full length human RPA70 was cloned into the MCS2 (Ndel/Xhol) restriction site 
of a pCOLADuet-1 vector (Table 3.2). Codons for these RPA subunits were optimized for 
expression in E. coli. The combinations of candidate sites chosen for each plasmid variant 
were based on the appropriate PIKK and CDK sites identified in previous studies [69].  
 
3.2.2 Recombinant Protein Expression  
BL21(DE3) E. coli cells were transformed with pACYCDuet-1 and pCOLADuet-1 
plasmids concurrently following methods provided by the supplier (Novagen) except for 
the incubation time in the shaking incubator following heat shock. The cells had to be 
incubated for a minimum of 30 minutes longer than the provided protocol recommended. 
Dual selection of cells occurred through growth on agarose plates containing 30 µg/ml 
kanamycin and 34 µg/ml chloramphenicol. If the cells were not given the additional time 
in the shaking incubator stated earlier then no colonies would form. Surviving colonies 
were selected and grown in LB media incubated at 37 °C with shaking at 170 RPM. Cells 
were grown until they reached an OD600 between 0.7 and 0.9, after which they were 
induced with 1 mM IPTG and incubated for 4 hours at 37 °C. Cells were pelleted by 
centrifugation at 14000 xg and stored at -20 °C. 
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RPA70 in pCOLADuet-1 RPA70 mutations 
wtRPA70 none 
2ERPA70 T180E, S207E 
1EaRPA70 S207E 
1EbRPA70 T180E 
  
RPA32/14 in pACYCDuet-1 RPA32 mutations 
wtRPA32/14 none 
9ERPA32/14 S4E;S8E;S12E;T21E;S23E;S33E;S52E;S72E;S174E 
8ERPA32/14 S4E;S8E;S12E;T21E;S23E;S33E;     S72E;S174E 
7EaRPA32/14 S4E;S8E;S12E;T21E;S23E;S33E;     S72E 
7EbRPA32/14 S4E;S8E;S12E;T21E;S23E;S33E;          S174E 
7EcRPA32/14 
6ERPA32/14 
2ERPA32/14 
1ERPA32/14 
S4E;S8E;S12E;T21E;S23E;S33E; S52E 
S4E;S8E;S12E;T21E;S23E;S33E 
                  S23E;S33E 
                  S23E 
Table 3.2 Plasmid combinations for expressing phosphomimetics of RPA 
Plasmids contained glutamic acid mutations for RPA70 or RPA32 candidate sites as 
listed above. If a plasmid contained the same number of phosphomimetic mutations 
as another plasmid, a letter was added to the name as a distinction. 
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3.2.3 Purification 
Protein purification was performed as described in the literature with the following 
changes [126]. The lysis buffer had 500 mM of sodium thiocyanate (NaSCN) and 0.1% 
(v/v) PIC (SIGMA) added to the HEPES Inositol (HI) buffer (30 mM HEPES, pH 7.8, 0.5% 
inositol, 0.25 mM EDTA and 2 mM 2-mercaptoethanol) and was used for resuspension of 
cells stored in pellet form (5 ml/g cell pellet). Cell lysis was achieved with three passes 
through an Emulsiflex-C3. Cell lysate was centrifuged at 40,000 xg and the supernatant 
was filtered using a 0.45 µm filter (EMD Millipore) to remove cellular debris. This clarified 
lysate was dialyzed against HI-200 mM KCl. An ÄKTApure was used for all column 
chromatography purification steps. The first step in purification for all RPA proteins was a 
HiTraptm Blue HP column (GE Lifesciences). This column was equilibrated with 5 CV of 
HI-0 buffer after which the clarified lysate was loaded using injections of up to 15 ml with 
7 CV of HI-0 buffer as a wash after each injection. After the column was loaded with the 
full lysate amount (25-50 ml) it was rinsed with 5 CV of HI-800 mM KCl buffer, followed by 
5 CV of HI-500 mM NaSCN. RPA heterotrimer elution takes place with a 5 CV step of HI-
750 mM NaSCN, which was collected and dialyzed into HI-200 mM KCl. The second step 
in purification used a column packed with ceramic hydroxyapatite (HAP) (BIO-RAD) using 
HI-0 as a running buffer and HI-160 mM sodium phosphate (NaPO4) to create an elution 
gradient. Protein solution was loaded onto the column as described previously, and a 20 
CV gradient from 0 to 100% HI-160 mM NaPO4 eluted the protein. To clean the column 1 
CV of HI-0 followed by 5 CV of HI-500 mM KPO4 was used, and the column was stored in 
0.5 M NaOH. The third purification step is a HiTraptm Q FF column. The protein solution 
from the HAP purification step was diluted with an additional 4 volumes of HI-0 buffer 
before being loaded onto the HiTraptm Q FF column. HI-0 was used as the running buffer, 
and an elution gradient was formed to HI-1M NaCl. The final step in purification was a 
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HiLoad 16/600 Superdex 200 pg column equilibrated with 1.3 CV of HI-300 mM KCl. 
Elution of RPA phosphomimetics occurred between 70 ml and 80 ml after injection, with 
1 ml fractions collected.  
 
3.2.4 Size Exclusion Chromatography with Multi-Angle Light Scattering 
Samples of phosphomimetic RPA were prepared by centrifugation at 13,000 xg for 
5 minutes, after which the sample was filtered using a 0.45 µM PVDF membrane syringe 
filter. If the sample volume was less than 100 µl an insert was used to assist in sample 
containment. SEC-MALS was performed as described in section 2.2.5. The running buffer 
for these experiments was HI-300 mM KCl. 
 
3.2.5 Surface Plasmon Resonance 
Samples prepared for SPR underwent the full 4 step purification process to ensure 
that no DNA contamination was present. This was confirmed through A260/280, for which all 
samples had values less than 0.7. SPR data was collected using an OpenSPR (Nicoya 
Lifesciences). For experiments involving the binding affinity between RPA and DNA the 
running buffer was phosphate buffered saline (PBS) (Fisher Bioreagents) supplemented 
with 1 M KCl, making the final concentration of the buffer 137 mM NaCl, 10 mM Na2HPO4, 
1.8 mM KH2PO4, 1002.7 mM KCl, pH 7.4. The regeneration buffer was 10 mM HCl, pH 2. 
Streptavidin sensor chips (Nicoya Lifesciences) with a 3’ Biotinylated 25-mer ssDNA 
ligand (sequence 5’-CCACCCCCCCCCCCCCCCCCCCCCC-3’) were utilized. Ligand 
was bound to the sensor chip at 20 µl/min while analyte samples and regeneration buffer 
flowed at 60 µl/min. After ligand was bound an average of seven injections of regeneration 
buffer was required to condition the sensor and provide a stable baseline. Injections of the 
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RPA analyte were performed using two hundred and fifty microliters of 250 nM, 125 nM, 
62.5 nM, 31.25 nM, and 15.625 nM concentrations. Kinetic analysis was performed using 
the TRACEDRAWER software package.   
 
3.3. Results 
3.3.1. Expression and Purification 
Seventeen combinations of phosphomimetic candidate sites were tested (Figure 
3.5). After transformation all combinations were checked for expression of all three 
subunits by SDS-PAGE. Using a HiTraptm Blue HP column followed by SEC with a 
Superdex 200 column it was found that 12 combinations would not form stable 
heterotrimers. Five combinations formed a stable heterotrimer (Figure 3.6). These five 
were put through the full four step purification protocol before being tested for DNA binding 
affinity using SPR (Figure 3.7).  
 
3.3.2. Size Exclusion Chromatography with Multi-Angle Light Scattering 
SEC-MALS showed that the combinations wtRPA70+9ERPA32/14, 
1EbRPA70+9ERPA32/14, 1EaRPA70+wtRPA32/14, 1EbRPA70+wtRPA32/14, and 
wtRPA70+2ERPA32/14 had a MW close to the expected 110 kDa (Table 3.3).  
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Figure 3.5 RPA phosphomimetic combinations and purification results  
RPA70 candidate site combinations are listed in columns (dark blue). RPA32/14 
candidate site combinations are listed in in rows (grey). Combinations resulting in 
purifiable heterotrimers are shown with a green background, with unsuccessful 
combinations shown with a red background. Cartoons of the RPA70, 32, and 14 
subunits indicate if the subunit was present at the end of purification, with overlapping 
cartoon subunits indicating if they purified in the same fraction.  
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Figure 3.6 Purified RPA phosphomimetics 
Proteins were purified using HiTraptm Blue affinity 
chromatography and SEC before being run on SDS-PAGE. 
Gel layout: 1) MW ladder, 2) wtRPA70+wtRPA32/14, 3) 
wtRPA70+9ERPA32/14, 4) 1EaRPA70+wtRPA32/14, 
5)1EbRPA70+wtRPA32/14, 6) 1EbRPA70+9ERPA32/14, 
7) MW ladder, and 8) wtRPA70+2ERPA32/14. 
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Figure 3.7 Four-step purified RPA phosphomimetics 
wtRPA and RPA phosphomimetics that could form stable heterotrimers purified using 
HiTraptm Blue affinity, Hitraptm Q FF affinity, HAP affinity, and SEC. 
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RPA Phosphomimetic Purified 
as a 
Trimer 
A
260/280
 Molecular 
Weight 
(kDa) 
Polydispersity mg 
yield/g of 
cells 
wtRPA70+wtRPA32/14 Yes .59 105.5 1.000 .27 
wtRPA70+9ERPA32 Yes 1.52 105.3 1.003 .16 
wtRPA70+2ERPA32/14 Yes .69 NA NA .45 
1EaRPA70+wtRPA32/14  Yes .45 108.6 1.000 .29 
1EbRPA70+wtRPA32/14 Yes .60 108.4 1.000 .14 
1EbRPA70+9ERPA32/14 Yes .82 106.3 1.000 .45 
Table 3.3 Purification and polydispersity of RPA phosphomimetics 
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3.3.3. Surface Plasmon Resonance 
 The affinity of wtRPA for ssDNA is known to be very high, with a KD 10-9 M [126]. 
Initial SPR experiments with wtRPA confirmed this (data not shown). To promote 
equilibrium binding 1M KCl was added to the buffer so that differences between each 
phosphomimetic could be seen, as 1 M KCl partially disrupts the binding between ssDNA 
and RPA. DNA binding affinity for the combinations of wtRPA70+wtRPA32/14, 
wtRPA70+9ERPA32/14, and wtRPA70+2ERPA32/14 were similar with KD values of 
6.7x10-8 M, 7.4x10-8 M, and 8.8x10-8 M respectively. In contrast the combinations of 
1EaRPA70+wtRPA32/14, 1EbRPA70+wtRPA32/14, and 1EbRPA70+9ERPA32/14 had 
significantly diminished affinity for ssDNA with values of 15.4x10-8 M, 13.2x10-8 M, and 
35.5x10-8 M. The 1EbRPA70+9ERPA32/14 combination required fitting with a two state 
reaction model (Figures 3.8, 3.9, 3.10, 3.11 and Table 3.4). 
 
3.4 Discussion 
3.4.1 Outcomes of Purification 
The standard RPA purification methods, A stepwise process involving Affigel Blue 
affinity, HAP affinity, strong anion exchange, and finally SEC, will produce very pure RPA. 
This process was lengthy and inefficient for the initial testing of the phosphomimetics. The 
process was streamlined in two ways. First, HAP affinity was removed from the 
procedures as it was not a robust step. Various combinations of the RPA 
phosphomimetics would, for reasons unknown, simply flow through the resin instead of 
binding. Second, QFF was also dropped from the shortened  
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Figure 3.8 SPR curves for wtRPA70+wtRPA32/14 and wtRPA70+9ERPA32/14 
Concentrations for each curve are 250 nM (black), 125 nM, (red), 62.5 nM (blue), 31.25 
nM (green), and 15.63 nM (yellow). 
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Figure 3.9 SPR curves for wtRPA70+2ERPA32/14 and 1EaRPA70+wtRPA32/14 
Concentrations for each curve are top: 250 nM (green), 125 nM, (yellow), 62.5 nM 
(black), 31.25 nM (red), 15.63 nM (blue), and bottom: 250 nM (black), 125 nM, (red), 
62.5 nM (blue), 31.25 nM (green), and 15.63 nM (yellow). 
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Figure 3.10 SPR curves for 1EbRPA70+wtRPA32/14 and 1EbRPA70+9ERPA32/14 
Concentrations for each curve are 250 nM (black), 125 nM, (red), 62.5 nM (blue), 31.25 
nM (green), and 15.63 nM (yellow). 1EbRPA70+9ERPA32/14 required fitting with a 
two-state binding reaction model. 
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Candidate Site 
Combinations 
Ka (1/(M*s)) Kd (1/s) KD (M) 
wtRPA70 + 
wtRPA32/14 
 
2.5x105 (4.2x104) 
 
 
1.5x10-2 (5.5x10-4) 
 
 
6.7x10-8 (.65x10-8) 
 
 
wtRPA70 + 
9ERPA32/14 
1.5x105 (1.4x104) 
 
1.1x10-2 (3.5x10-4) 
 
 
7.4x10-8 (.50x10-8) 
 
 
wtRPA70 + 
2ERPA32/14 
 
1.6x105 (7.6x103) 
 
1.4x10-2 (3.2x10-4) 
 
 
8.8x10-8 (.22x10-8) 
 
 
1EaRPA70 + 
wtRPA32/14 
 
1.1x105 (6.7x103) 
 
1.7x10-2 (1.5x10-4) 
 
 
15.4x10-8 (.86x10-8) 
 
 
1EbRPA70 + 
wtRPA32/14 
 
9.9x104 (5.4x103) 
 
1.3x10-2 (3.5x10-4) 
 
 
13.2x10-8 (.72x10-8) 
 
 
Two-State Binding 
Candidate Site 
Combinations 
Ka1 
(1/(M*s)) 
Kd1 (1/s) 
 
Ka2 (1/s) 
 
Kd2 (1/s) 
 
KD (M) 
1EbRPA70 + 
9ERPA32/14 
 
4.6x104 
(4.5x103) 
 
 
3.7x10-2 
(3.3x10-3) 
 
4.1x10-3 
(1.5x10-4) 
1.8x10-3 
(3.1x10-5) 
35.5x10-8 
(5.8x10-8) 
 
 
   
Table 3.4 Phosphomimetic RPA DNA binding affinity 
Average values from three experiments are given with standard deviation in 
parenthesis. Experiments were done in triplicate. Only the 1EbRPA70+9ERPA32/14 
required fitting with a two-state binding reaction model. 
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Figure 3.11 Respective KD values of phosphomimetic RPA combinations 
wtRPA70+wtRPA32/14 had a KD of 6.7x10-8 M. 
wtRPA70+2ERPA32/14 had a KD of 8.8x10-8 M. 
wtRPA70+9ERPA32/14 had a KD of 7.4x10-8 M. 
1Ea(S207E)RPA70+wtRPA32/14 had a KD of 15.4x10-8 M. 
1Eb(T180E)RPA70+wtRPA32/14 had a KD of 13.2x10-8 M. 
1Eb(T180E)RPA70+9ERPA32/14 had a KD of 35.5x10-8 M. 
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protocols as it would purify the phosphomimetics regardless of whether they formed a 
heterotrimer or not. QFF fractions containing RPA also contained enough impurities to 
obscure the RPA subunits when examined by SDS-PAGE, making it difficult to select 
fractions to use if further purification steps. For these reasons HiTraptm Blue affinity was 
kept as the first step, but the second and final step for these experiments was SEC. 
HiTraptm Blue affinity allowed for not only the initial robust selection of the RPA 
phosphomimetics, but it also provided the step where DNA contamination was removed. 
SEC proved to be the perfect second step as it was a gentle yet thorough procedure to 
ensure that the recovered RPA was bound together in its heterotrimer form. RPA 
phosphomimetics that would not form stable heterotrimers had their subunits purify into 
separate fractions as monomers or heterodimers.  
We tested 17 combinations of RPA70 and RPA32/14 candidate sites, of which 12 
proved unstable and could not be purified into a heterotrimer by the method described 
above (Figure 3.5). Failure of the RPA phosphomimetics to form a stable heterotrimer 
was most often correlated with a distinct overexpression of the RPA32 subunit compared 
to total soluble protein when checked by SDS-PAGE. Of the 12 combinations that were 
unable to form a heterotrimer only four did not overexpress RPA32, namely, 
2ERPA70+wtRPA32/wtRPA14 wtRPA70+6ERPA32/14, wtRPA70+7EcRPA32/14, and 
wtRPA70+1ERPA32/14. It is predicted that phosphomimetics that were unable to form a 
stable heterotrimer but were still able to pass the Affigel Blue affinity step were able to find 
a binding partner to stabilize their interaction with the Affigel Blue resin or were stabilized 
by the resin itself. There were 7 ways that these combinations failed to form heterotrimers. 
(1) The combinations of 2ERPA70+9ERPA32/14, 2ERPA70+8ERPA32/14, 
1EaRPA70+9ERPA32/14, 1EaRPA70+8ERPA32/14, wtRPA70+7EaRPA32/14, and 
wtRPA70+7EbRPA32/14 all produce RPA70 in a separate purified fraction and a stable 
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RPA32/14 heterodimer. (2) The wtRPA70+8ERPA32/14 combination produced only a 
stable RPA32/14 heterodimer with no RPA70 detectable in any fractions. (3) The 
1EbRPA70+8ERPA32/14 combination showed the RPA70/14 subunits in a single fraction 
with RPA32 alone in a separate fraction. (4) 2ERPA70+wtRPA32/14 assembled into a 
trimer but the RPA70 subunit showed significant degradation. (5) wtRPA70+6ERPA32/14 
generated RPA70 and RPA14 in separate fractions with no RPA32 in any fractions. (6) 
wtRPA70+7Ec RPA32/14 exhibited RPA70 and RPA32 together in an early fraction, and 
then RPA70 in multiple later fractions without RPA32 or RPA14 present. (7) Finally, 
wtRPA70+1ERPA32/14 yielded RPA70, RPA32, and RPA14 all in separate fractions. As 
RPA32/14 have been found to be soluble on their own but RPA70 is not this makes 
circumstances 1,3, and 5-7 stand out, as they involve either RPA70 alone or with an 
incomplete RPA32/14 [126, 127]. The successful purification of the control combination 
wtRPA70 and wtRPA32/14 indicates that the above failures were not due to the pET Duet 
system used for expression. Indeed, 5 of the 17 RPA70 and RPA32/14 phosphomimetic 
combinations were able to be purified as intact heterotrimers and were as follows: 
wtRPA70+9ERPA32/14, 1EbRPA70+9ERPA32/14, 1EaRPA70+wtRPA32/14, 
1EbRPA70+wtRPA32/14, and wtRPA70+2ERPA32/14. When examined by SDS-PAGE, 
mutated subunits run noticeably higher, which is typical. Only the wtRPA70+9ERPA32/14 
candidate combination purified with DNA contamination as indicated by its A260/A280 of 1.52 
(Table 3.3). This implies that this combination has retained ssDNA through the purification 
process and means that it may have different ssDNA binding properties. When this 
combination was taken through all four steps of purification the DNA contamination was 
removed, allowing it to still be tested for DNA affinity by SPR in later experiments. 
Examination of these proteins by SEC-MALS showed that all tested combinations were 
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monodisperse except for the wtRPA70+9ERPA32/14 combination, which is likely a result 
of impurities or ssDNA contamination.  
 
3.4.2 RPA Phosphoisoforms in G2 phase in control cells 
 The majority of RPA in cells exists in a phosphorylated state. Currently, the 
majority of cell-free experiments do not reflect this in their methodology, choosing to 
instead use wtRPA for protein:protein interactions. Experiments with physiologically 
relevant forms of RPA require the use of stable phosphomimetics. The phosphomimetic 
combinations of wtRPA70+1ERPA32 and wtRPA+2ERPA32/14 were tried. These 
combinations were selected due to the constant phosphorylation of S23 or S23 and S33 
due to the position in the cell cycle (Figure 3.2). We were surprised to find the combination 
of wtRPA70+1ERPA32 would not purify, as western blotting showed its presence in 
control cells, and capillary isoelectric focusing has confirmed that species of RPA with a 
single phosphorylation can be found in the cell (Figure 3.1). The combination of 
wtRPA+2ERPA32/14 was purifiable. When this combination was tested by SPR it was 
found to have ssDNA affinity lower than but still similar to that of wtRPA. The KD values 
were 8.8x10-8 M and 6.7x10-8 M respectively (Table 3.4). It is possible that this 
combination reflects one of the phosphorylation states observed in control cells (Figure 
3.1, blue line). 
 
3.4.3 RPA Phosphoisoforms in G2 After Induction of Double Strand Breaks 
 There are up to 14 phosphorylation sites on nine isoforms of RPA in cells with 
DSBs. (Figure 3.1, pink line). Out of the sixteen DSB phosphomimetic combinations 
tested, we found four isoforms that would purify as stable heterotrimers: 
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wtRPA70+9ERPA32/14, 1EaRPA70+wtRPA32/14, 1EbRPA70+9ERPA32/14, and 
1EbRPA70+wtRPA32/14. When DNA binding affinity was examined by SPR we 
discovered some very interesting results. Phosphomimetic combinations containing 
mutations solely on the RPA32 subunit had KD values similar to the 6.7x10-8 M of wtRPA, 
as wtRPA70+9ERPA32/14 and wtRPA+2ERPA32/14 had KD values of 7.4x10-8 and 
8.8x10-8 respectively. Combinations with Glu mutations on RPA70 significantly decrease 
the ssDNA binding affinity when compared to wtRPA (Table 3.4, Figure 3.11). This in 
itself is not terribly surprising, as the majority of the ssDNA binding affinity for RPA is the 
result of DBD-A and –B on the RPA70 subunit, so modifications here would likely have a 
stronger result. The combinations of 1EaRPA70+wtPA32/14 and 
1EbRPA70+wtRPA32/14 had values of 15.4x10-8 M and 13.2x10-8 M respectively. These 
values are almost double that of wtRPA. There was surprising data with the fact that 
1EbRPA70+9ERPA32/14, the phosphomimetic RPA with mutations on both the RPA70 
and the RPA32 subunit, had such a drastic drop in ssDNA affinity compared to all the 
others. The 1EbRPA70+9ERPA32/14 combination had a KD 35.5x10-8 M, significantly 
higher than even 1EaRPA70+wtPA32/14 and 1EbRPA70+wtRPA32/14 (Figure 3.4, 
Figure 3.11). A second unexpected detail about this combination is that it required fitting 
with a two state reaction model. This indicates this combination is acting as if the initial 
binding of ssDNA is enhancing the binding of a second ssDNA binding site, a phenomenon 
not observed in the other tested phosphomimetic combinations. From interpreting all of 
this data together we find an interesting possibility. All of the RPA phosphomimetics that 
contained RPA70 mutations had significantly reduced ssDNA binding affinity. It is 
therefore possible that the phosphorylation state that allows for RPA to pass ssDNA to 
RAD52 in the HR pathways is based on RPA70 phosphorylation. As the DBDs with the 
highest ssDNA affinity on RPA are located on the RPA70 subunit, and phosphomimetic 
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mutations to this subunit result in the most drastic changes in KD, it is possible that these 
mutations are somehow changing the way that RPA interacts with DNA through a 
conformational shift. This conformational shift may be altering RPA:ssDNA binding in a 
fashion that is more conducive to other proteins binding or interacting with the ssDNA and 
replacing RPA on the ssDNA. 
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Chapter IV: Conclusion and Future Directions 
4.1 Conclusion 
 RAD52(1-303) has been purified to a quality that renders it monodisperse and of 
a quality compatible with SAXS analysis. Using the orientation we found for the RAD52(1-
212) molecule we were able to extend that alignment to the RAD52(1-303) SAXS 
envelope. This places the DNA binding region of RAD52 facing upwards from the larger 
spherical region while the unstructured C-terminal strands occupy the lower, smaller 
diameter space. SAXS structures are low resolution however, so further experiments need 
to be performed to learn more about how the RAD52 molecule behaves, specifically how 
it interacts with phosphorylated and unphosphorylated RPA.  
RPA is usually phosphorylated in normal cells, with between one and four 
phosphorylations being the most common isoforms. When DSBs are present up to 14 
phosphorylations can be detected. However, cell free experiments using RPA do not 
reflect this, and often use RPA with no post-translational modifications. If the interactions 
of RPA are to be accurately investigated, then information on the effects of RPA’s 
phosphorylation state need to be discovered. Using western blot data [69] from cells 
without DSBs identifying RPA with a single phosphorylation (S23) in S phase and two 
phosphorylations (S23 and S33) in G2 phase we created Glu phosphomimetic mutants of 
those combinations. Surprisingly, the S23 mutant was unstable and could not be purified. 
The S23/S33 mutant could be purified and showed a DNA binding affinity akin to that of 
wtRPA. As both of these are CDK phosphorylation sites and S23 phosphorylation has 
been identified without accompanying S33 phosphorylation, it is surprising that a mutation 
to a single site induces instability while mutation of both of them results in a stable protein. 
As this phosphomimetic may represent RPA with a basal level of phosphorylation, further 
characterization experiments should be performed. After narrowing down a list of DSB 
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induced phosphorylation sites to eleven candidate sites we tested 15 different 
combinations of those sites. The four combinations of wtRPA70+9ERPA32/14, 
1EaRPA70+wtRPA32/14, 1EbRPA70+9ERPA32/14, and 1EbRPA70+wtRPA32/14 were 
found to form stable heterotrimers. ssDNA affinity of these combinations was tested using 
SPR, and it was found that 1EaRPA70+wtRPA32/14,1EbRPA70+wtRPA32/14, and 
1EbRPA70+9ERPA32/14 all had significantly lower ssDNA binding affinity than wtRPA. In 
addition, 1EbRPA70+9ERPA32/14 had significantly reduced ssDNA affinity when 
compared to both 1EaRPA70+wtRPA32/14 and 1EbRPA70+wtRPA32/14, as well as 
required fitting with a two state reaction model. All other tested combinations did not 
require this. These results are surprising because they show that the significant decreases 
seen in these mutants all involved a mutation to the RPA70 subunit. It is possible that 
these RPA70 mutations are inducing some form of conformational change that could make 
the ssDNA more accessible to other DNA binding proteins, or at least makes it easier for 
other DNA binding proteins to remove RPA from the ssDNA strand. If that is the case, 
then it is possible that one of the RPA70 phosphomimetic mutations tested in these 
experiments is the site responsible for allowing the transfer of ssDNA from RPA to RAD52 
in HR. More experiments are required to characterize these phosphomimetic mutants to 
find the correct DSB relevant form of RPA. 
 
4.2 Future Directions 
Structural analysis of RAD52(1-303) can be improved through a number of 
methods. The first of these would be by performing the X-ray scattering of either the whole 
RAD52(1-303) molecule or just the RAD52(212-303) domain in the presence of a strong 
magnetic field. This would restrict the motion of the CTDs allowing for potential fiber 
diffraction (personal communication with Scott Barton of SAXSLAB and [128]).  
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Experiments to break up the RAD52 ring also show potential to produce more 
SAXS structures to be used for further identification of the various regions of RAD52(1-
212) and RAD52(1-303). The small molecule 6-hydroxy-dopa has been previously 
identified to break the undecameric ring into dimers [129]. This drastic change in oligomer 
state, if it could be purified to a quality compatible with SAXS analysis, would give a very 
different view of the RAD52(1-303) molecule and its C-terminal region. If the results could 
be made monodisperse, it may even be possible to use this technique to acquire SAXS 
data on full length RAD52. 
The addition of RPA(172-270) (the wHLH domain) to RAD52(1-303) would also be 
of interest. The wHLH domain could bind to the previously identified CTD sequence, and 
this “decoration” of the CTD could restrict movement and alter the SAXS envelope, 
highlighting the bound region. This kind of experiment may also have an unexpected 
outcome, as recent experiments have shown that the KD between RAD52(1-303) and the 
RPA32(172-270) is approximately 1.2x10-9 M using SPR (Mona Al-Mugotir, unpublished 
data). This is a stark contrast to the information presented in the Mer et al. (2000) which 
said that the binding between RPA(172-270) and RAD52(257-274) had a KD ≈ 10-6 M. A 
binding simulation (G. Borgstahl, unpublished data) between RPA(172-270) and 
RAD52(1-303) did not show RPA(172-270) binding the RAD52(257-274) region in the 
CTD, but instead showed it binding in the region where the RAD52 CTD connects to the 
RAD52(1-212) crystal structure. This information is worth following up on, as depending 
on the actual properties of this binding the wHLH domain could be what breaks up the 
RAD52 ring. If this is true, that means it could be possible to form crystals of RAD52(1-
303) and RPA(172-270), and discover the true interaction between these two molecules. 
Experiments to use SEC-MALS to investigate the interaction between RAD52(1-303) and 
RPA(172-270) were attempted, but not completed. It was found that salt concentrations 
92 
 
low enough to promote binding between the two molecules also promoted binding 
between RAD52(1-303) and the SEC column (unpublished data). These experiments 
were attempted with a WTC-050S5 column but the protein bound to the column. The 
experiments should be continued with a different SEC column, for instance one that is 
Superose based such as the one used in Deng et al. (2009). 
Concerning RPA phosphomimetics, first and foremost the table of the 
phosphomimetic combinations presented in this document is incomplete (Figure 3.5). 
There is a chance that other combinations which can form stable trimers have not been 
identified. To this end, the rest of the table should be filled in by a future student to identify 
any other stable isoforms of RPA phosphomimetics. 
We are currently generating preliminary data on phosphomimetic RPA binding with 
RAD52 using SPR. For these experiments RAD52 is bound to a NTA sensor chip and the 
RPA phosphomimetics are tested for interaction. If an RPA phosphomimetic is found to 
have different or improved binding with RAD52 then it can be used to plan follow-up 
experiments on the ssDNA:RPA:RAD52 complex as employed by Deng & coworkers 
[130]. The RPA phosphomimetic that affects the complex in a similar way to truly 
phosphorylated RPA could be identified. Deng noted a handoff of ssDNA from RPA to 
RAD52 when RPA was phosphorylated; our data suggests this could be caused by RPA70 
phosphorylation.  
Dr. Alexander Mazin at Drexel University will be testing the ability of the RPA 
phosphomimetics to promote inverse strand exchange with DNA and RNA using the assay 
described in his paper [92], further assisting with the identification and validation of the 
appropriate RPA phosphomimetic. 
The identification of the relevant RPA phosphomimetic will allow for the SAXS 
analysis of the ssDNA:RPA:RAD52 complex, giving insight into the mechanism behind 
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how this complex forms, including the characteristics of the actual binding surfaces 
between these proteins.  
 Finally, the activity of the phosphomimetics could be investigated in human cells 
and tested for biological phenotype. RPA could be knocked out, and rescue experiments 
performed to identify how each of the previously validated phosphomimetics interacts with 
the various DNA repair pathways. This would be very difficult to do, as RPA is an essential 
protein and interference in its activities is extremely harmful to cells. These experiments 
are possible though, and clustered regularly interspaced short palindromic repeats 
(CRISPR)/ CRISPR associated protein 9 (Cas9) (CRISPR/Cas9) gene editing combined 
with short hairpin DNA (shDNA) knockdown targeting the 5’ untranslated region (UTR) of 
the wtRPA subunits show promise for conducting these experiments. 
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Appendix 1 
Introduction 
RPA contains two domains which are traditionally responsible for its interaction 
with other proteins. The first of these is the RPA70(1-120) region, also known as domain 
F, and RPA32(200-270), known to contain the wHLH domain. Structural evidence exists 
of interaction between the wHLH domain and peptides of the UNG, XPA, and RAD52 
proteins [54]. This protein’s affinity for RAD52 makes it a point of interest for determining 
the full structural interaction between RPA and RAD52. To this end, attempts to crystallize 
RPA70(172-270) and examine the stoichiometry of RAD52(1-303)/RPA32(172-270) 
interaction were attempted. 
 
Expression of RPA32(204-270) 
The sequence for RPA32(204-270) was cloned into pET28a vector by Dr. Marc 
Wold (GenScript) and was a gift. BL21(DE3) E. coli cells were transformed using the 
manufacturers protocol (Novagen). Selection of cells occurred through growth on agarose 
plates containing 30 µg/ml kanamycin. Surviving colonies were selected and grown in LB 
media incubated at 37 °C and shaken at 170 RPM. Cells were grown to an OD600 
between 0.7 and 0.9, after which they were induced with 1 mM IPTG and incubated for 4 
hours at 37 °C. Cells were pelleted by centrifugation at 14000 xg and stored at -20° C. 
 
Purification of RPA32(204-270) 
RPA32(204-270) was purified as in Mer G. et. al (2000) with the following changes. 
A HisTraptm HP column was equilibrated with 5 CV of 10 mM NaPO4, pH 7.5, 150 mM 
NaCl, 10 mM imidazole, 2 mM BME, running buffer before the protein was loaded. Elution 
occurred using a gradient to 1M imidazole. The protein peak was collected and dialyzed 
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into 20mM NaPO4, 50mM NaCl, 2mM BME, pH 7.5 running buffer for anion exchange. A 
HiTraptm Q FF column was used for the anion exchange step. The running buffer was the 
same as the dialysis buffer listed above, and elution was accomplished by a gradient to 
1M NaCl. Elution of the protein occurred at 335 mM NaCl. At this point the protein was a 
single band when examined by SDS-PAGE. Proteins to be used for crystallography were 
additionally purified by SEC using HiLoad 16/60 Superdex 75 pg (GE Lifesciences). The 
running buffer for SEC was 10mM Tris-HCl, 170mM NaCl, 2mM BME, 0.5mM EDTA. Due 
to a lack of Trp amino acids in this protein and the fact that the Bradford as `say 
was not found to be reliable, it was necessary to use a Microplate BCAtm Protein Assay 
Kit – Reducing agent Compatible (ThermoScientific) to determine the concentration of the 
protein. This assay was performed as per the manufacturer’s instructions, and was read 
on a ELx808 plate reader. 
 
Dynamic Light Scattering of RPA32(204-270) 
DLS was performed as described in section 2.2.3. The protein was easily made 
monodisperse using this purification protocol, and would typically have a polydispersity of 
12.5% (Figure A.1). 
 
SEC-MALS of RPA32(204-270) 
SEC-MALS was performed as described in section 2.2.4. Experiments involving 
the binding of RAD52(1-303) and RPA32(204-270) were done with multiple running 
buffers. It was determined that a salt concentration of 175 mM KCl was too high to allow 
interaction between the proteins. The salt type and concentration was adjusted over 
multiple experiments until reaching a low salt value of 50 mM NaCl. During this process 
the proteins switched from not interacting with each other, to having RAD52 bind strongly  
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Figure A.1 RPA32(204-270) DLS 
The average polydispersity of monodisperse wHLH fractions was 12.5%  
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with the column, and at no middle value could the proteins be detected as interacting. A 
column using different packing material should be used for future experiments. 
 
Crystal Trays of RPA32(204-270) 
RPA wHLH that retained its monodispersity was concentrated to 20 mg/ml and 
used for setting up crystal trays. The majority of these trays showed that RPA wHLH was 
more soluble than expected, and did not precipitate very often at the concentrations used. 
The following commercial crystallization condition screens were attempted: NeXtal 
Anions, NeXtal MPD, NeXtal pH Clear 2, NeXtal The Classics, NeXtal The Classics Lite, 
NeXtal AmSO4, NeXtal Cations, NeXtal PEGS, NeXtal PEGSII, NeXtal Cryos, NeXtal 
Cryos 1 & 2, Hampton Index, Hampton Index II, Hampton HT, Hampton JCSG Core I, 
Emerald Biosystems Cryo 1 & 2, and Molecular Dimensions Midas. 
 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis Results of Tested 
Phosphomimetic Combinations 
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Figure A.2 SDS-PAGE of wtRPA70+2ERPA32/14 
1) Ladder, 2) wtRPA, 3) pre-induction cells, 4) post-induction cells, 5) wtRPA, 6) ladder, 
7) cell lysate, 8) Affigel Blue flow-through, 9) 800 mM KCl fraction, 10) 500 mM NaSCN 
fraction, 11) 1500 mM NaSCN fraction, 12) SEC input sample, 13) wtRPA, 14) ladder, 
15-20) SEC fractions 
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Figure A.3 SDS-PAGE of wtRPA70+1ERPA32/14 
1) Ladder, 2) pre-induction cells, 3) post-induction cells, 4) wtRPA, 5) ladder, 6)wtRPA, 
7) cell lysate, 8) Affigel Blue flow-through, 9) 800 mM KCl fraction, 10) 500 mM NaSCN 
fraction, 11) 1500 mM NaSCN fraction, 12) wtRPA, 13) ladder, 14) wtRPA, 15-21) SEC 
fractions, 22) wtRPA 
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Figure A.4 SDS-PAGE of wtRPA70+7EcRPA32/14 
1) wtRPA, 2) ladder, 3) pre-induction cells, 4) post-induction cells, 5) wtRPA, 6) ladder, 
7) cell lysate, 8) cell pellet, 9) clarified supernatant, 10) Affigel Blue flow-through, 11) 
800 mM KCl fraction, 12) 500 mM NaSCN fraction, 13) 1500 mM NaSCN fraction, 14) 
wtRPA, 15) ladder, 16-18) SEC fractions 
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Figure A.5 SDS-PAGE of wtRPA70+6ERPA32/14 
1) Ladder, 2) pre-induction cells, 3) post-induction cells, 4) ladder, 5) wtRPA, 6) cell 
pellet, 7) cell lysate, 8) Affigel Blue flow-through, 9) 800 mM KCl fraction, 10) 500 mM 
NaSCN fraction, 11) 1500 mM NaSCN fraction, 12) wtRPA, 13) ladder, 14-17) SEC 
fractions 
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Figure A.6 SDS-PAGE of wtRPA70+1EbRPA32/14 
1) Ladder, 2) pre-induction cells, 3) post-induction cells, 4) ladder, 5) wtRPA, 6) cell 
pellet, 7) cell lysate, 8) Affigel Blue flow-through, 9) 800 mM KCl fraction, 10) 500 mM 
NaSCN fraction, 11) 1500 mM NaSCN fraction, 12) ladder, 13) wtRPA, 14-16) SEC 
fractions. 
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Figure A.7 SDS-PAGE of wtRPA70+7EaRPA32/14 
1) Ladder, 2) wtRPA, 3) pre-induction cells, 4) post-induction cells, 5) wtRPA, 6) 
ladder, 7) clarified cell lysate, 8) Affigel Blue flow-through, 9) 800 mM KCl fraction, 10) 
500 mM NaSCN fraction, 11) 1500 mM NaSCN fraction, 12) SEC input sample, 13) 
ladder, 14) wtRPA, 15-17) SEC fractions 
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Figure A.8 SDS-PAGE of 1EbRPA70+8ERPA32/14 
1) Ladder, 2) wtRPA, 3) pre-induction cells, 4) post-induction cells, 5) ladder, 6) 800 
mM KCl fraction, 7) 500 mM NaSCN fraction, 8) 1500 mM NaSCN fraction, 9-10) 
wtRPA, 11) ladder, 12-19) SEC fractions 
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Figure A.9 SDS-PAGE of 1EbRPA70+9ERPA32/14 
1) Ladder, 2) wtRPA, 3) post-induction cells, 4) wtRPA, 5) ladder, 6) cell lysate, 7) cell 
pellet, 8) Lysate after dialysis, 9) Affigel Blue flow-through, 10) 800 mM KCl fraction, 
11) 500 mM NaSCN fraction, 12) 1500 mM NaSCN fraction, 13) SEC input sample, 
14) ladder, 15) wtRPA, 16-20) SEC fractions 
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Figure A.10 SDS-PAGE of 1EbRPA70+wtRPA32/14 
1) Ladder, 2) pre-induction cells, 3) post-induction cells, 4) ladder, 5) Affigel Blue flow-
through, 6) 500 mM NaSCN fraction, 7) 1500 mM NaSCN fraction, 8) SEC input 
sample, 9) ladder, 10-11) SEC fractions 
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Figure A.11 SDS-PAGE of wtRPA70+8ERPA32/14 
1) wtRPA, 2) ladder, 3) pre-induction cells, 4) post-induction cells, 5) ladder, 6-7) 800 
mM KCl fractions, 8) 500 mM NaSCN fraction, 9-16) 1500 mM NaSCN fractions, 17) 
wtRPA, 18) ladder, 19-22) SEC fractions 
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Figure A.12 SDS-PAGE of wtRPA70+9ERPA32/14 
1) Ladder, 2) pre-induction cells, 3) post-induction cells, 4) ladder, 5-7) 1500 mM 
NaSCN fractions, 8) SEC fraction, 9) wtRPA, 10) ladder 
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Figure A.13 SDS-PAGE of 1EaRPA70+8ERPA32/14 
1) Ladder, 2) wtRPA, 3) pre-induction cells, 4) post-induction cells, 5) cell pellet, 6) cell 
lysate, 7) Affigel Blue flow-through, 8) 500 mM NaSCN fraction, 9) 1500 mM NaSCN 
fraction, 10) SEC input sample, 11) wtRPA, 12) ladder, 13-17) SEC fractions 
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Figure A.14 SDS-PAGE of 1EaRPA70+9ERPA32/14 
1) Ladder, 2) pre-induction cells, 3) post-induction cells, 4) wtRPA, 5) ladder, 6-10) 
SEC fractions, 11) wtRPA 
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Figure A.15 SDS-PAGE of 1EaRPA70+wtRPA32/14 
1) Ladder, 2) pre-induction cells, 3) post-induction cells, 4) ladder, 5-6) SEC fractions 
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Figure A.16 SDS-PAGE of 2ERPA70+8ERPA32/14 
1) Ladder, 2) pre-induction cells, 3) post-induction cells, 4) post dialysis cell lysate, 5) 
Affigel Blue flow-through 6) 800 mM KCl fraction, 7) 500 mM NaSCN fraction, 8) 1500 
mM NaSCN fraction, 9) SEC input sample, 10-11) wtRPA, 12) ladder, 13-18) SEC 
fractions 
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Figure A.17 SDS-PAGE of 2ERPA70+9ERPA32/14 
1) wtRPA, 2) ladder, 3) Affigel Blue flow-through, 4) 800 mM KCl fraction, 5) 500 mM 
NaSCN fraction, 6) 1500 mM NaSCN fraction, 7) ladder, 8) wtRPA, 9-12) SEC 
fractions 
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Figure A.18 SDS-PAGE of 2ERPA70+wtRPA32/14 
1) Ladder, 2) supernatant from uninduced cells, 3) cell pellet from uninduced cells, 4) 
supernatant from induced cells, 5) pellet from induced cells, 6) ladder, 7) 500 mM 
NaSCN fraction, 8-11) 1500 mM NaSCN fractions, 12) ladder, 13) SEC fraction 
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Figure A.19 SDS-PAGE of wtRPA 
1) Ladder, 2) pre-induction cells, 3) post-induction cells, 4) ladder, 5-8) 800 mM KCl 
fractions, 9-15) 1500 mM NaSCN fractions, 16) ladder, 17-25) SEC fractions 
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